Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2019

Pharmacological assessment of adjuncts to enhance mu-opioid
receptor agonist antinociception in male rhesus monkeys: Does
one + one = three?
Jeremy Cornelissen
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Behavior and Behavior Mechanisms Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/6115

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

1

Pharmacological assessment of adjuncts to enhance mu-opioid receptor agonist
antinociception in male rhesus monkeys: Does one + one = three?

Jeremy Christopher Cornelissen

A thesis/dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Pharmacology & Toxicology at Virginia Commonwealth University.

©

Jeremy C. Cornelissen
All Rights Reserved

2019

2
Table of Contents
Acknowledgements …………………………………………………………………….……. 3
Abstract ……………………………………………………………………………………… 4
Chapter 1: Introduction ……………………………………………………………………… 5
Chapter 2: Determining the utility of the NMDA receptor antagonists ketamine and MK-801 as
candidate adjuncts to MOR agonists in the selective production of anti-allodynia using doseaddition analysis in male rhesus monkey …………………………………………………… 28
Chapter 3: Identifying potential pharmacological determinants of the antinociceptive interaction
between NOP receptor agonist adjunct, Ro 64-6198, and MOR agonists in male rhesus monkeys
…………………………………………………………………………………………………63
Chapter 4: Expansion of the Furchgott equation for receptor theory by investigating the potential
for fixed-proportion mixtures of a competitive MOR antagonist and MOR agonist to manipulate
antinociceptive efficacy in male rhesus monkeys ………………………………...………… 88
Chapter 5: Discussion ………………………………………………………………………. 119
References …………………………………………………………………………………... 135

3

Acknowledgements
The author would like to acknowledge his advisory committee, Drs. Matthew Banks, Steve
Negus, Katherine Nicholson, Kimberle Jacobs, and Pamela Knapp for their assistance in steering
the research discussed herein and thoughtful editing of this document. Further he would like to
specifically thank Drs. Banks and Negus for their patience, instruction, and aid in writing the
manuscripts which comprise Chapters 2, 3, and 4. The author would also like to express his
profound gratitude to the Dept. of Pharmacology & Toxicology, specifically Drs. Dewey and
Akbarali, for their support through his tenure in the Doctoral program. Finally, the author would
like to thank the technical expertise of both Floyd Steele and Rebekah Tenney in several of the
experiments discussed herein.

4
Abstract
Mu-opioid receptor (MOR) agonists are effective agents for pain management, but are
also limited by a number of undesirable effects. One approach to enhance the therapeutic effects
and minimize the undesirable effects of MOR agonists may be to combine MOR agonists with
an adjunct targeting a different receptor system. This targeted medical approach, known as
“combination therapy”, aims to augment the desired effects of the MOR agonist (i.e.
antinociception) and/or diminish the undesirable deleterious side effects of the MOR agonist.
This dissertation investigated the utility of this approach in an assay of thermal nociception and
schedule-controlled responding in male rhesus monkeys with three aims. One aim determined
the utility of N-methyl D-aspartate (NMDA) receptor antagonists to selectively enhance MOR
agonist antinociception. A second identified the pharmacological determinants of antinociceptive
interactions between a nociceptin opioid peptide (NOP) receptor agonist and MOR agonists. A
third aim investigated the potential for fixed-proportion mixtures of a competitive MOR
antagonist and MOR agonist to manipulate antinociceptive efficacy. Experimental results did not
support the utility of NMDA antagonists as adjuncts to selectively enhance MOR agonist
antinociception. Furthermore, the antinociceptive interactions between a NOP agonist and MOR
agonists were modest and occurred under a narrow range of conditions. Finally, fixed proportion
MOR antagonist-agonist mixtures were effective in manipulating antinociceptive in vivo
efficacy. In conclusion, this dissertation does not provide strong empirical evidence that a
combination therapy approach will result in clinically effective and selective enhancement of
MOR agonist analgesia. The dissertation concludes with proposed strategies and novel
preclinical methods to enhance preclinical-to-clinical translation of effective candidate
analgesics.
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Chapter 1: Introduction
Pain as a Problem
Pain is defined as “an unpleasant sensory and emotional experience associated with
actual or potential tissue damage or described in terms of such damage” (IASP, 2017). Pain, and
the management thereof, remains a significant healthcare challenge in the United States and
worldwide. The estimated financial burden on society associated with patients suffering from
some aspect of pain is over 550 billion dollars annually (Gaskin and Richard, 2012). Moreover,
nearly one-third of Americans reported at least one pain symptom within the past three months,
and nearly one-fifth of American adults are afflicted with chronic pain (Nahin et al, 2015;
Dahlhamer et al, 2018). Chronic pain is defined as pain persisting for greater than one month,
and it is often comorbid with various other disorders, ranging from arthritis to cancer (IASP,
2017). Additionally, pain symptoms are a common reason to visit a medical professional in
developed countries (Schappert et al, 2006). Furthermore, between 2006 and 2016, more than
215 million opioid-based prescriptions were written each year (CDC, 2018). Unfortunately, this
high rate of opioid prescriptions has contributed to the current opioid crisis in the United States
(Delgado et al, 2018). Taken together, the financial, societal, and individual burdens emanating
from pain and its treatment highlight the need for preclinical research to develop novel
analgesics and/or strategies to enhance the therapeutic effects and minimize the undesirable
effects of opioids for pain management.
Brief History on Opioid Agonists as Analgesics
Opioid agonists are one of the longest used psychoactive substances known to man, save
for alcohol and marijuana. However, throughout much of human history, opioid use was limited
to the opium poppy (Papaver somniferum), and until relatively recently, the plethora of opioid
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compounds currently available to modern medicine remained undiscovered. While some
archaeological discoveries of Papaver date back over 8000 years, the earliest evidence of
cultivation and use can be traced back to Sumer in 3400 BCE based on the discovery of stone
tablets referring to the opium poppy as “Huy Gil”, which is roughly translated to “Joy Plant”
(Brownstein, 1993). This example is merely the earliest widely accepted finding, as nearly every
major society after Sumer has some evidence of opium utilization either for recreational or
medicinal purposes (Brownstein, 1993; Presley and Lindsley, 2018).
While nearly a millennium would pass before a scientific understanding of the nature by
which opium produces its abuse-related and medicinal effects would arise, opium was readily
utilized during antiquity. Knowledge of the medicinal properties of the opium poppy quickly
disseminated from Sumer to the Assyrians to the Egyptians to the Grecians, etc. During these
times, opium use was most commonly associated with ritualistic and religious rites, as evidenced
by various fables of its bestowment upon man by various gods and their close association with
poppies in numerous visual representations (Schiff Jr, 2002). However, there was some evidence
of opium use for medicinal purposes, namely for euthanasia, when opium would be mixed into a
cocktail with poison hemlock (Conium maculatum) (Brownstein, 1993).
The Islamic societies of the early Middle Ages were some of the first to begin
rudimentary investigations into cataloging the physiological effects of opium in medical texts
and initiated the introduction of opium to the Far East via the Silk Road (Brownstein, 1993;
Presley and Lindsley, 2018). Moreover, the famous physician and author of Cannon of Medicine,
Avicenna, was the first to catalog many of opium’s physiological effects including: analgesia,
antitussive, gastrointestinal distress, respiratory depression, neuromuscular disturbances,
hypnosis, and somnolence. However, perhaps more impressive and innovative for the time, was
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Avicenna’s recommendations for delivery and dosages of opium. This marked some of the first
instances of opium standardization for medicinal use (Heydari et al, 2013). This text and its
subsequent translation to Latin was a key factor in introducing opium to Western medicine,
where its medicinal potential and use blossomed during the Renaissance (Smith, 1980).
Since their initial cultivation and through the modern day, the alkaloids of interest that
are present in opium poppy have been extracted in a similar manner. When the plant is ready to
be harvested, the bulb is scored with a blade, and a milky wax, usually referred to as opium latex,
pours from the bulb. Once the latex has dried, it is dissolved in boiling water to remove any
impurities. When enough liquid has been boiled off, a waxy residue is left, called smoking opium
(Presley and Lindsley, 2018). Although Papaver somniferum contains various alkaloids, there
are six that are generally thought to contribute to the prototypical physiological and
psychological effects of opioids. These six alkaloids are morphine, codeine, thebaine, narceine,
noscapine, and papaverine.
Scientific Advancements to Improve Therapeutic Effects and Minimize Undesirable Effects
Following the initial isolation of morphine from opium poppy by Sertürner in 1804, there
was a steady increase in the isolation of naturally occurring opioid alkaloids and synthesis of
synthetic opioid compounds (Courtwright, 2009). For example, codeine was first isolated in
1832 by Robiquet. Felix Hoffman synthesized the first synthetic opioid, heroin, in 1897 (Science
History Institute, 2019). Throughout the 20th century, a number of new synthetic opioid
compounds were generated including: oxycodone, methadone, meperidine, fentanyl, nalbuphine,
and buprenorphine (Cowan et al, 1977; Sneader, 2005). Buprenorphine’s synthesis also marked
one of the first attempts to intentionally improve opioid analgesics. The rationale was to create a
low efficacy opioid agonist that would still produce pain relief while having an improved safety
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profile (i.e. reduced incidence of respiratory depression). The drug design approach for
buprenorphine lead to another experimental approach of reducing undesirable opioid side effects
and increasing antinociceptive potency or efficacy by combining an opioid with an adjunct
compound active at another receptor system (O’Connell et al, 2014; Li, 2019; Viscus, 2019).
The concepts of potency and efficacy are important pharmacological factors in the
context of opioid pharmacology. Potency is “a measure of drug activity expressed in the terms of
the amount required to produce an effect of given intensity”, whereas efficacy is the maximal
response produced by a drug (Neubig et al, 2003; Holford and Sheiner, 1981). For example, in
the context of opioids, buprenorphine is highly potent drug as its antinociceptive effects are
apparent at relatively low doses; however, buprenorphine is a low efficacy drug as it can only
produce antinociception (i.e. the action of blocking the detection of a noxious stimulus) against
relatively low noxious stimulus intensities (Walker, Zernig, and Woods, 1995). In contrast,
methadone is not a potent drug, but is a high efficacy drug, as it will produce antinociception
against relatively high noxious stimulus intensities (Mello and Mendelson, 1985; Cornelissen et
al, 2019). Further, potency and efficacy are not always negatively correlated as the previous
examples may suggest. For example, fentanyl is a very potent, highly efficacious opioid (Finch
and DeKornfeld, 1967; France et al, 1992). Potency and efficacy are important defining factors
in the overall behavioral effects of opioid drugs and have the potential to be manipulated in an
attempt to improve the clinical utility of these compounds.
Drug adjuncts are secondary compounds administered in conjunction with another
primary drug in a targeted medical approach known as “combination therapy”. This practice has
been successfully implemented for the treatment of a variety of disorders ranging from
neurological to cardiovascular etiologies (Li, 2019). Moreover, adjuncts are a particularly
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attractive drug development method because it allows for the potential repurposing of currently
FDA-approved medications to facilitate the drug development and clinical trial processes (Li,
2019). This approach is also employed in the pain field (e.g. Vicodin), and could potentially
serve as one method to enhance or retain the therapeutic effects while also minimizing the
undesirable effects of opioids (Collins et al, 2018). In the context of these experiments, an
adjunct, which could increase opioid antinociceptive potency, would result in less opioid agonist
being administered to produce similar antinociceptive effects, whereas increasing opioid
antinociceptive efficacy would be expressed as the opioid and adjunct combination producing a
greater antinociceptive maximal effect compared to the opioid alone (Li, 2019).
The notion of combining an opioid with another compound(s) acting at a different
receptor target is not a recent development in medicine. For example, opium was commonly
combined with poison hemlock for the purposes of euthanasia in antiquity; further, spongia
somnifera, a sponge soaked with a cocktail of: opium, mandrake, poison hemlock, and henbane
(Hyoscyamus niger), was utilized as an early anesthetic in Europe during the Middle Ages
(Brownstein, 1993; Prioreschi, 2003). Laudanum (from the Latin meaning, “worthy of praise”) is
perhaps the earliest example of an opioid combination medication in direct efforts to treat pain
(Potter, 1902). While laudanum’s initial creation is credited to the Swiss physician Paracelsus, it
is disputed as to whether or not his original “recipe” indeed included opium (Sigerist, 1941).
Nevertheless, laudanum first gained notoriety as an analgesic following the English physician
Thomas Sydenham’s Medical Observations Concerning the History and Cure of Acute Diseases
publication where he described the opium and ethanol tincture’s exact measurements for the
mixture (Davenport-Hines, 2004). Therefore, laudanum probably represents the first example of
an opioid combination medication for pain management.

10
Regardless of whether or not the ethanol “adjunct” of laudanum augmented opium’s
analgesic effects, Brompton cocktail was the first opioid combination developed with that
explicit goal. Brompton cocktail was comprised of: an opioid agonist (morphine or heroin),
cocaine, high-percentage alcohol, chloroform, and syrup (to increase palatability) (Richardson
and Baker, 1956). The Brompton cocktail was used in both post-operative and palliative care
regularly during the 1920s (Clark, 2014). Moreover, the elixir was reported to be a superior
analgesic compared to morphine alone in palliative care units (Melzack, Mount, & Gordon,
1979). Although Brompton cocktail did succeed in augmenting opioid agonist-induced analgesia,
more recent investigations suggest this was a non-selective enhancement. For example, some
heroin/cocaine dose mixtures have been shown to engender greater drug-taking behaviors than
heroin alone in preclinical drug self-administration procedures (Mello et al, 1995; Negus, 2005).
As attempts to identify additional opioid combination medications progressed, so did the
aspiration for their ability to selectively enhance analgesia and even potentially mitigate
undesirable opioid effects (Smith, 2008; Li, 2019).
The most typically prescribed opioid combination medications utilize oxycodone or
hydrocodone as the mu-opioid receptor (MOR) agonist and a non-steroidal anti-inflammatory
drug (NSAID), such as ibuprofen, or acetaminophen (e.g. Percodan(R), Percocet(R),
Vicoprofen(R), Vicodin(R)) (Raffa et al, 2010; Li, 2019). Although there is limited clinical or
preclinical evidence of any additive or synergistic interactions between these two classes when
co-administered, one hypothesis is that NSAID-induced cyclo-oxygenase-2 (COX-2) inhibition
or acetaminophen augments the opioid-mediated analgesic effect (Raffa et al, 2010).
Unfortunately, NSAIDs and acetaminophen have their own undesirable effects such as
gastrointestinal bleeding, cardiovascular complications, and hepatotoxicity (Sostres et al, 2010).
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Thus, there is a need for preclinical research to develop and evaluate candidate opioid adjuncts
that enhance the therapeutic effects and minimize the undesirable effects in the context of pain
management.
There are at least four potential approaches for the opioid+adjunct to produce an “opioidsparing effect” (which is defined as a “reduction in the opioid dose administered without a loss in
analgesic efficacy” (Nielsen et al, 2017)): (1) Prolong analgesia duration, (2) enhancement of
analgesic efficacy, (3) enhancement of analgesic potency, (4) minimization or elimination of
undesirable opioid-related effects (Smith, 2008; Li, 2019; Viscusi et al, 2019). Currently,
NSAIDs and acetaminophen are the only opioid adjuncts available in an FDA-approved
prescription medication. Thus, knowledge regarding the usefulness of this approach to improve
opioid analgesics is relatively limited. Accordingly, the aim of this dissertation was to examine
candidate opioid agonist adjuncts to selectively modulate opioid antinociception in preclinical
assays of nociception.
Basic Opioid Pharmacology and Modulation of Nociception
MOR agonists are a class of molecules that bind to and activate the MOR receptor. The
MOR receptor is one of the three “classical” opioid receptors, the other two being the deltaopioid receptor (DOR) and the kappa-opioid receptor (KOR) (Stein, 2016). The different
classifications of these receptors are based on their peptide structure and the preferential binding
of the three main endogenous opioids to them. For example, endorphins preferentially bind to
MORs, enkephalins to DORs, and dynorphins to KORs; however, these neuropeptides are not
selective and there is some overlap in binding profiles across the three opioid receptors (Stein,
2016). There also exists a fourth subtype of opioid receptor, the nociceptin-opioid peptide (NOP)
receptor; however, the NOP receptor is not considered a “classical” opioid receptor due to
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significant differences in the peptide composition of the receptor and NOP receptor insensitivity
to the opioid antagonist naltrexone (Stein, 2016; Toll et al, 2016).
All three classical opioid receptors and the NOP receptor are G-protein coupled receptors
(GPCR) which, when activated, initiate a cascade of intracellular signaling events altering
cellular function (Bohn et al, 1999; Stein, 2016). All opioid receptors are coupled to a specific Gprotein categorized as a Gi/o and are composed of three subunits: alpha, beta, and gamma. The
alpha subunit is a GTPase, which hydrolyzes the molecule guanosine triphosphate (GTP) to
release energy contained in the phosphodiester bond at the gamma phosphate of the GTP
molecule. The latter two subunits form a beta-gamma complex (Goldstein et al, 1971; Manglik et
al, 2012; Wu et al, 2012; Thompson et al, 2012). Ligand binding to the opioid receptor initiates
an intracellular signaling cascade following a conformational change of the receptor. This allows
dissociation of the alpha subunit and beta-gamma complex from the receptor. Once this occurs,
the alpha subunit inhibits production of the secondary messenger cyclic adenosine
monophosphate (cAMP) and the beta-gamma complex activates multiple G protein-coupled
inwardly-rectifying potassium (GIRK) channels and inhibits calcium channels (Ingram and
Williams, 1994; Tedford and Zamponi, 2006; Luscher and Slesinger, 2010). The beta-gamma
complex also inhibits sodium channels, hyperpolarization-activated cyclic nucleotide-gated
(HCN) channels, transient receptor potential vanilloid (TRPV1) channels, and acid-sensing ion
channels (ASICs) in dorsal root ganglion (DRG) neurons. Furthermore, the beta-gamma complex
can also modulate pre- and post-synaptic cellular excitability by inhibition of glutamatemediated excitatory post-synaptic potentials (EPSPs) (Herz et al, 1989; Endres-Becker et al,
2007; Spahn et al, 2013; Cai et al, 2014). The net result of these intracellular events is an
increase in membrane potential and decreased likelihood of an action potential (Stein, 2016).

13
Although mu, delta, kappa, and NOP receptors share similar signaling mechanisms,
differences in receptor density and neuroanatomic locations result in differential pharmacological
effects. For example, MOR agonists produce euphoria and respiratory depression, which are two
of the major undesirable effects of clinically available opioid analgesics (Hamilton and Cullen,
1953; Levitt et al, 1977; Montandon and Slutsky, 2019). DOR agonists can produce convulsions,
KOR agonists can produce dysphoria (Tortella et al, 1983; Wadenberg, 2003), and NOP agonists
may impair learning and memory (Toll et al, 2016). Similar to the opioid receptors’ overlap in
function, there is also a generous overlap in the distribution of these receptors across the nervous
system. As the focus of this dissertation is on modulating nociception, the most pertinent location
of opioid receptors (and specifically MORs) is along the spinothalamic tract.
The anterolateral pain processing system is the most prominent nociceptive pathway
responsible for transmitting noxious stimuli information from the periphery to the brain (Kandel
et al, 2013). This pathway projects from primary nociceptors along primary afferents -neurons
that transmit information to the central nervous system (CNS) - that synapse in the outer laminae
of the dorsal horn of the spinal cord, which in turn project to the thalamus and then relays the
nociceptive signal to a number of different cortical regions (Kandel, 2013). The anterolateral
pain processing system includes myelinated Aδ fibers and unmyelinated C fibers, both of which
carry the nociceptive signal from the periphery to the CNS. Aδ fibers and C fibers each encode
different types of sensory stimulation from the periphery, and each are innervated by both highand low- threshold mechanoreceptors. The major difference between the two is the speed at
which they will conduct an action potential. Aδ fibers tend to transmit more rapidly, while C
fibers more slowly, and this discrepancy is due to the differences in myelination (Aδ fibers are
myelinated, and C fibers are not) (Traub and Mendell, 1988). Furthermore, the anterolateral pain
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processing system is also comprised of descending efferent neurons (i.e. neurons that transmit
information away from the CNS). Descending neurons project from the parabrachial nucleus and
rostroventral medulla to the soma (i.e. neuronal cell body) of nociceptive afferents in the dorsal
horn of the spinal cord and are responsible for modulating nociceptive signals being transmitted
from the periphery (Kandel, 2013). Some opioid receptors have been shown to have similar
effects on transmission of such nociceptive signals. Mu, kappa, and delta receptor activation
have all been shown to inhibit nociceptive signaling along the anterolateral pain processing
system at the level of the periphery (Ko et al, 1999, 2000; Butelman et al, 2004). However, the
effect of NOP receptor activation is less certain. Existing data contradictorily suggest that the
endogenous ligand nociceptin/orphanin FQ (N/OFQ) can both produce antinociception (Ko et al,
2002) and block MOR-, DOR-, and KOR-mediated antinociception (Chen et al, 2007). It is
through modulation of nociceptive signaling by opioids and/or novel compounds along this
pathway that many preclinical assays assess the utility of candidate analgesics.
Preclinical Assessment of Candidate Analgesics
The preclinical investigation of candidate analgesics or opioid adjuncts involves three
major components. The first component is research subject selection. Nonhuman primates
(NHPs) are the most phylogenetically similar preclinical research subjects to humans, and their
utilization should enhance vertical translation from preclinical to clinical results. Furthermore,
the distribution and density of opioid receptor subtypes is much more similar between NHPs and
humans than rodents and humans (Weerts, 2007). For example, rodents have a higher ratio of
delta:mu receptors than do humans or nonhuman primates. Beyond this, several potential MOR
adjuncts have been previously shown to have differential effects in rodents than in NHPs (Weerts
et al, 2007). In addition, one of the independent variables manipulated in this dissertation is
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MOR agonist efficacy, and differences in MOR agonist efficacy have been reported such that
NHPs are more representative of MOR agonist antinociceptive efficacy in humans than rodents
(Walker et al, 1993, 1995; Maguire and France, 2014; Cornelissen et al, 2018b).
The second component is the noxious stimulus and there are numerous types of
experimental noxious stimuli. This dissertation utilized a thermal noxious stimulus, specifically
warmed water. In a warm-water tail withdrawal procedure, a subject’s (e.g. rhesus monkey) tail
is immersed in a container of warmed water hypothesized to be noxious (50 or 54 °C) and the
latency for the animal to remove its tail is measured (Dykstra and Woods, 1986). Candidate
analgesics or adjuncts can then be administered to determine if administration leads to an
increased tail withdrawal latency indicative of an antinociceptive effect. For example, the MOR
agonist morphine produces dose-dependent antinociception (Dykstra and Woods, 1986). These
results and more recently published results suggest that this procedure is sensitive to clinically
used opioid analgesics (Walker et al, 1993; Gatch et al, 1998; Negus et al, 2009; Banks et al,
2010a,b; Maguire and France, 2014; Cornelissen et al, 2018a,b; Cornelissen 2019). However, the
warm-water tail withdrawal procedure is known to have poor behavioral selectivity and thus is
susceptible to false positives due to motor suppression or incoordination (Whiteside et al, 2013;
Negus, 2019).
To facilitate interpretation of results in the warm-water tail withdrawal procedure, a
second behavioral procedure was utilized in this dissertation to provide one metric of behavioral
selectivity. Schedule-controlled responding has been used since the early 1960’s to determine
pharmacological properties of drugs related to potency, time course, and receptor mechanisms
(Cook and Kelleher, 1962; Kelleher and Morse, 1964). Initially, the procedure was developed to
determine if some drug effects were more sensitive to positively reinforced behaviors as opposed
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to negatively reinforced behaviors (i.e. shock-avoidance tasks) (Cook and Kelleher, 1962). The
procedure utilizes animal subjects that have been trained to respond on a manipulandum at a
predetermined (typically) ratio or interval for the presentation of a food reinforcer. Once
behavior is stable, drugs can then be administered to the animal to investigate drug or dose
related effects on operant rates of responding. The rate-decreasing effects of opioids in NHPs
have been well characterized, and there is strong concordance between studies regarding the
potency rankings for opioids to produce decreases in rates of responding (Negus et al, 1993;
Butelman et al, 1996; Negus et al, 2003, Stevenson et al, 2003, 2005; Banks et al 2010a,b;
Cornelissen et al, 2018a,b, 2019). Moreover, there is a strong consensus that efficacy is an
important determinant in this procedure with low efficacy opioids producing limited rate
suppression and high efficacy opioids producing greater to even full rate suppression (Cook and
Kelleher, 1962; Byrd, 1975; Howell et al, 1988; Negus et al, 1993; Negus et al, 2003; Stevenson
et al, 2005; Banks et al, 2010; Cornelissen, et al, 2018a,b; Cornelissen et al 2019). Thus, this
dissertation utilized these two experimental assays (warm-water tail withdrawal and schedulecontrolled responding) to address the following three specific aims:

1.) Determining the utility of the NMDA receptor antagonists ketamine and MK801 as candidate adjuncts to MOR agonists in the selective production of antiallodynia using dose-addition analysis in male rhesus monkeys.

One receptor system that might be a biological target of interest for potential adjuncts to
MOR agonists in combination medication therapy is the glutamate system. The N-methyl Daspartate (NMDA) receptor is a cation-selective ion channel found throughout the central
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nervous system (CNS), which is preferentially permissible to sodium, potassium, and calcium
(Vyklicky et al, 2014). The endogenous ligand is the glutamate neurotransmitter, and functional
receptors are tetramers comprised of two GluN1 subunits in combination with two additional
subunits: two GluN2s, two GluN3s, or one of each (Monyer et al, 1992; Ulbrich & Isacoff,
2008). Current NMDA receptor channel gating models suggest that ligand binding induces a
conformational change promoting the closure of the ligand-binding domain and opening of the
cation channel. Interestingly, the molecular binding requirements for NMDA receptor activation
are dictated by the presence of specific subunits. To this end, GluN2 containing tetramers require
binding of 2 glutamate molecules and 2 glycine co-agonist molecules (Watkins & Evans, 1981;
Johnson & Ascher, 1987). GluN3 containing tetramers are activated solely upon glycine binding
and are much more sparsely expressed in the CNS (Pérez-Otaño et al, 2016). Beyond this, a
magnesium ion is bound in the ion channel pore when the NMDA receptor is inactive, must be
displaced to allow intracellular cation flux (Furukawa et al, 2005).
Three lines of evidence support the evaluation of NMDA receptor antagonists as MOR
agonist adjuncts. First, glutamate is not merely the primary excitatory neurotransmitter in the
CNS, but also serves a critical role in the transmission of nociceptive impulses from the
periphery to cortical regions through the spinal cord via the spinothalamic tract (Westlund et al,
1992; Meldrum, 2000). Anatomical studies have demonstrated the presence of NMDA receptors
at both the spinal level within the dorsal horn and supraspinal level in nociceptive pathways
(Rodriguez-Munoz et al, 2012; Bourbia et al, 2014). More specifically, immunolocalization
experiments in NHPs (Macaca fascicularis) have indicated that nearly half of spinothalamic
tract-contacting cells contained glutamatergic terminals (Westlund et al, 1992). Given the role of
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glutamate in nociceptive transmission along the spinothalamic tract, we hypothesized that that
inhibition of glutamate transmission should dampen nociceptive transmission.
Second, a number of NMDA receptor antagonists produce antinociception in multiple
preclinical models of pain across a number of different animal species. In mice, it has been
demonstrated that: (1) memantine and ketamine are antinociceptive in an assay of acetic acidinduced writhing (Malec et al, 2008) and (2) MK-801 and ACEA-1011 prevent the development
of formalin-induced nociception (Vaccarino et al, 1993). Furthermore, in rats, NMDA receptor
antagonists have shown antinociceptive effects at both the cellular and organismal level.
Administration of the compound 7-chlorokynurenate (7CK) reduced activity (i.e. action potential
firing rates) of dorsal horn C-fibers (Dickenson and Aydar, 1991) and this finding was expanded
upon with ketamine and MK-801-induced antinociception in an assay of lactic acid-induced
stretching (Hillhouse and Negus, 2016). Finally, the antinociceptive effects of ketamine, MK801, phencyclidine (PCP), and dextrorphan have been demonstrated in rhesus macaques using an
assay of thermal nociception (France et al, 1989). These findings have been interpreted to
suggest that NMDA antagonists such as ketamine might have analgesic properties and serve as
candidate MOR agonist adjuncts.
Lastly, several preclinical studies have supported the utility of NMDA receptor
antagonists as adjuncts to MOR agonists across several pain states and model organisms. For
example, ketamine was shown to potentiate the acute antinociceptive effects of the MOR
agonists morphine, fentanyl, and sufentanil in mice, but not the antinociceptive effects of the
DOR agonist SNC80 or the KOR agonist U50,488H (Baker et al, 2002). Furthermore, in rats, the
active ketamine metabolites S(+)- and R(-)-norketamine enhanced morphine-induced
antinociception in models of: thermal nociception, peripheral neuropathy, and inflammation
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(Holtman Jr et al, 2008). Finally, MK-801, (-)-6-phosphonomethyl-decahydroisoquinoline-3carboxylic acid (LY235959), and (+)-(1-hydroxy-3-aminopyrrolidine-2-one) ((+)-HA-966) all
increased the electric shock intensity tolerated by squirrel monkeys (Saimiri sciureus) compared
to morphine alone (Allen and Dykstra, 2001). Overall, these preclinical studies are supported by
clinical evidence suggesting that although ketamine has undesirable effects, it also may serve as
a useful adjunct to mu agonists (for review and recent meta-analysis, see Lee and Lee, 2016).
This dissertation evaluated NMDA antagonist and MOR agonist interactions using a
preclinical capsaicin-induced thermal allodynia procedure. Allodynia is defined as the expression
of a pain-related pain elicited by a stimulus that is normally innocuous and can be apparent in
various clinical conditions including post-operative pain, cancer, and arthritis (Ko et al, 1998;
IASP, 2017). Preclinically, allodynia can be evoked via transdermal capsaicin application (Ko et
al, 1998). Capsaicin is a pungent vanilloid irritant found in chili peppers of the genus Capsicum
and is responsible for producing their “spicy” flavor. Capsaicin binds to and activates the
transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor (Caterina et
al, 1997). As a non-selective cation channel, TRPV1 activation increases membrane potential
(Caterina et al, 1997). Transdermal capsaicin application will elicit a transient burning sensation
in both humans and NHPs and results in allodynia by lowering nociceptive thresholds; thus,
capsaicin application may model inflammatory clinical pain states (Simone et al, 1987, 1989; Ko
et al, 1998). Ketamine has been proposed to possess anti-inflammatory properties (De Kock et
al., 2013; Wang et al., 2013). Moreover, results from our own laboratory have challenged the
claim that either ketamine or MOR/ketamine combinations produce antinociception against acute
noxious stimuli, and opioid/NMDA antagonist interactions have not been previously assessed in
preclinical allodynia models (Banks et al, 2010a). Finally, capsaicin stimulates glutamate release
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from sensory afferents, and is sensitive to blockade via activation of peripheral MORs (Winter et
al, 1995; Ko et al, 1998). Taken together, this background strongly supports the investigation of
opioid/NMDA combinations in models of allodynia that are responsive to peripheral opioid
activation. Thus, antinociceptive interactions were assessed using an assay of capsaicin-induced
thermal allodynia. We hypothesized that NMDA antagonists would selectively enhance mu
agonist-induced antinociception vs. mu agonist-induced rate suppression.

2.) Identifying potential pharmacological determinants of the antinociceptive
interaction between the NOP receptor agonist adjunct, Ro 64-6198, and MOR
agonists in male rhesus monkeys.

Another potential receptor system that might function as a useful mu opioid agonist
adjunct is the nociceptin opioid peptide (NOP) system. The NOP receptor is a Gi/o-coupled
GPCR and considered to be the “non-classical” fourth opioid receptor (Toll et al, 2016). The
NOP receptor is activated by the endogenous opioid peptide known as nociceptin/orphanin FQ
(N/OFQ) and, unlike the 3 “classical” opioid receptors, is relatively insensitive to antagonism by
naltrexone (Toll et al, 2016). Moreover, a paucity of commonly employed exogenous opioid
ligands are active at the NOP receptor and produce agonist-like effects except for buprenorphine,
and this activity is typically only apparent at very high doses (Khroyan et al, 2009). [(1S,3aS)-8(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5]decan-4-one (Ro
64-6198) is a highly selective and efficacious experimental small molecule NOP receptor agonist
that has contributed to our improved understanding of NOP receptor functions (Jenck et al, 2000;
Dautzenberg et al, 2000). While Ro 64-6198 was initially synthesized as a potential treatment for
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Alzheimer’s, depression, or stress disorders, targeting these indications with NOP receptor
agonists have not been successful (Jenck et al, 2000; Dautzenberg et al, 2001). Moreover, the
receptors are expressed in cortical brain regions and throughout the spinal cord implicating a
potential role in antinociception, anxiety, and reinforcement (Toll et al, 2016). Two lines of
evidence support potential interactions between mu-opioid and NOP receptors.
First, NOP receptors are colocalized with mu-opioid receptors in both spinal and brain
regions involved in nociceptive signaling pathways (for review, see Toll et al., 2016). For
example, both the NOP and MOR receptor are expressed in ascending and descending pathways
of the spinothalamic tract and in nociceptive processing/modulatory regions such as
somatosensory cortex, thalamus, parabrachial nucleus, rostral ventral medulla, spinal cord, and
within the DRG (Neal et al, 1999; Florin et al, 2000; Toll et al, 2016). More specifically, NOP
receptors in the dorsal horn are mainly distributed through the deep laminae I-III, which is
important for antinociception (Toll et al, 2016). Thus, due to NOP receptor localization,
activation of NOP receptors would be hypothesized to produce antinociception.
Second, preclinical studies have reported species difference in the antinociceptive effects
of both NOP activation by the endogenous ligand and the selective high-efficacy NOP agonist
Ro 64-6198 (Jenck et al, 2000; Ko et al, 2008). Intrathecal administration of N/OFQ produced
antinociceptive effects in nonhuman primates, but biphasic effects on antinociception in mice
(Ko et al, 2009). Moreover, systemic Ro 64-6198 produced antinociception in rhesus monkeys
(Ko et al, 2009), but not rodents (Reiss et al, 2008). Further highlighting potential species
differences, systemic combinations of Ro 64-6198 and a mu-opioid agonist produced additive
antinociceptive effects in mice (Reiss et al, 2008), but synergistic antinociceptive effects in
rhesus monkeys (Cremeans et al, 2012).
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Overall, this literature supports further evaluation of NOP and mu-opioid agonist
interactions. Previous studies examining mu-opioid agonist antinociceptive interactions with
other receptor systems suggest that one important determinant of these interactions may be MOR
agonist efficacy (Banks et al, 2010b; Maguire and France, 2014; Negus et al, 2009). However,
the degree to which mu-opioid agonist efficacy is a determinant of NOP agonist interactions is
unknown. Therefore, the aim of the present study was to determine the role of mu-opioid ligand
efficacy in antinociceptive interactions with the NOP agonist Ro 64-6198 in rhesus monkeys
using previously described procedures (Banks et al, 2010a,b; Stevenson et al, 2003).
Antinociceptive interactions between Ro 64- 6198 and six mu-opioid ligands (17cyclopropylmethyl- 3,14β-dihyroxy-4,5α-epoxy-6α-[(3 ́ -isoquinolyl)acetamindo]morphinan
(NAQ), buprenorphine, nalbuphine, morphine, oxycodone, and methadone) that vary in agoniststimulated GTPγS binding from lowest to highest (Selley et al, 1998; Thompson et al, 2004;
Zaidi et al, 2013) and in their in vivo effectiveness to produce antinociception (Cornelissen et al,
2018b) were investigated. For comparison, Ro 64-6198 interactions were also investigated with
the selective high efficacy KOR agonist nalfurafine. Nalfurafine is not a clinically-approved
analgesic and fails to produce antinociception under conditions that dissociate antinociception
from behavioral sedation (Endoh et al, 2001; Lazenka et al, 2018). Drug interactions were also
examined in an assay of schedule-controlled responding in a different cohort of monkeys to
assess behavioral selectivity to produce antinociception vs. rate suppression. If NOP agonists are
to be considered as candidate MOR agonist adjuncts, then we would hypothesize that Ro 646198 would robustly and selectively enhance the antinociceptive vs. rate suppressant effects of
mu-opioid agonists.
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3.) Expansion of the Furchgott equation for receptor theory by investigating the
potential for fixed-proportion mixtures of competitive MOR antagonist and
MOR agonist to manipulate antinociceptive efficacy in male rhesus monkeys.

The Furchgott equation was developed to generate theoretical curves of receptor
activation level across a range of agonist doses (Ruffolo, 1982). The equation considers both
agonist and antagonist values including dose, efficacy, affinity, transduction function, and
receptor number to generate an “estimate” of drug effects. The Furchgott equation applies to
both in vivo and in vitro procedures measuring varying levels of receptor activation. The present
aim expanded the Furchgott equation to predict the in vivo effects of a fixed-proportion agonistantagonist mixture.
Fixed-proportion mixtures have been used in both preclinical experimental models and in
clinically used medications. For example, the application of dose-addition analysis to determine
the relationship (e.g. subadditive, additive, supra-additive) between two drugs relies upon the
generation of fixed-proportion mixtures to adequately probe a wide enough range of drug
combinations to best identify an effect. Moreover, several opioid combination medications
employ a fixed-proportion mixture (either with an opioid antagonist or other drug). For example,
the medications suboxone(R) (buprenorphine/naloxone) and Targin(R) (oxycodone/naloxone)
use a fixed-proportion approach in their dosing (Simpson et al, 2008; Yokell et al, 2011).
Furthermore, Targin(R) utilizes an opioid antagonist to mitigate the undesirable MOR agonist
effect constipation. This example represents one potential advantage of a fixed-proportion
agonist-antagonist approach.
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Pharmacodynamics is concerned with the affinity and efficacy of drugs at their receptor
targets. Drug affinity can be precisely measured with ligand binding techniques, but drug
efficacy to activate receptor signaling and produce downstream effects is a relative measure
dependent in part on the signaling pathway(s) and downstream effects under consideration, and
drug efficacies are typically described in relation to some standard high-efficacy ligand (Ruffolo,
1982; Kenakin, 2012). Although efficacy is challenging to measure, it is clearly relevant in drug
development. For example, mu-opioid receptor (MOR) ligands differ in their efficacy to activate
MOR-coupled signal transduction processes and produce MOR-mediated effects such as
analgesia and respiratory depression. Fentanyl has high MOR efficacy and increasing fentanyl
doses can produce both antinociception and lethal respiratory depression (Gerak et al., 1994;
Banks et al., 2010a; Ding et al., 2016). At the other extreme of the efficacy continuum,
naltrexone has little or no MOR efficacy, produces no agonist effects, and functions as a
competitive reversible antagonist (Walker et al., 1994; Ko et al., 1998; Bowen et al., 2002).
Between these extremes are intermediate-efficacy MOR ligands such as nalbuphine and
buprenorphine, which produce submaximal stimulation of MOR signaling and a subset of
agonist effects that includes analgesia but only weak respiratory depression (Gerak et al., 1994;
Pitts et al., 1998; Kishioka et al., 2000). Experiments to investigate the expression and
consequences of ligand efficacy at MORs or other receptor targets can be useful both to (1)
determine the efficacy required to produce different effects of interest, and (2) evaluate relative
efficacy of new ligands as they are developed.
One common approach to efficacy evaluations relies on the use of irreversible antagonists
to evaluate the impact of reducing receptor number on expression of drug effects (Furchgott,
1966; Kenakin, 1993; Bergman et al., 2000). Efficacy requirements for different effects can be
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estimated, because an irreversible antagonist will produce greater antagonism of effects with
high- versus low-efficacy requirements (Zernig et al., 1997). Relative efficacies of different
drugs can be estimated, because an irreversible antagonist will produce greater antagonism of a
low- versus high-efficacy agonist (Zimmerman et al., 1987; Walker et al., 1998). However,
studies with irreversible antagonists can be logistically challenging (e.g., due to the long duration
of antagonist effects), and irreversible antagonists are not available for many receptors of
interest. Decreases in receptor number can also be accomplished with genetic mutations, as in
heterozygous and homozygous receptor knockout animals (Grim et al., 2016), but the degree of
control over the magnitude of that decrease is limited. Receptor theory suggests an alternative,
more precise, and more flexible strategy to investigate efficacy using mixtures of competitive
agonists and antagonists. Figure 1 (left panel) shows a theoretical dose-effect function for a highefficacy agonist administered alone or in the presence of increasing fixed doses of an antagonist.
The familiar result is an antagonist dose-dependent rightward shift in the agonist dose-effect
curve (Ko et al., 1998; Negus et al., 2003). Figure 1 (right panel) shows theoretical effects using
a different experimental design, in which the agonist is administered in combination with fixedproportional doses of the antagonist, such that increasing agonist doses are administered in
combination with increasing antagonist doses. In this design, the antagonist is expected to
produce proportion-dependent downward shifts in the agonist dose-effect curve, and mixtures
with decreasing agonist-to-antagonist proportions have decreasing apparent efficacies to activate
the receptor. This approach has two potential advantages relative to existing strategies. First,
agonist-to-antagonist proportion can be precisely manipulated to yield precise increments in
efficacy. Second, this approach could be applied to any receptor system for which a competitive
agonist and antagonist are available.
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Figure 1. Theoretical curves simulated from the Furchgott equation for receptor theory (Ruffolo, 1982). Left panel shows
rightward shifts in a competitive reversible agonist dose-effect function after pretreatment with increasing fixed doses of
a competitive reversible antagonist. Right panel shows downward shifts in a competitive reversible agonist dose-effect
function when agonist and antagonist are co-administered in fixed-proportion mixtures. Equations and definitions of
terms are shown below the panels. For this simulation, agonist dose A and antagonist dose B vary in KD (i.e., at a dose of
1, dose = KD); RT was set arbitrarily at 100, and all other variables were set arbitrarily at 1. Note that in the left panel,
antagonist dose is a fixed proportion p of the agonist dose A, such that B = pA and increased in agonist dose are
accompanied by increases in antagonist dose.

The goal of Aim 3 was to test the utility of this approach using the MOR agonist fentanyl
and competitive antagonist naltrexone (Negus et al., 1993; Emmerson et al., 1994, 1996; Walker
et al., 1994). Effects of these drugs administered alone and in fixed-proportion mixtures were
determined in an assay of thermal nociception using two thermal stimulus intensities (50 and
54°C warm water) and compared with effects produced by six other MOR ligands shown
previously to vary in their relative MOR efficacies in in vitro assays of agonist-stimulated
GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001; Thompson et al.,
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2004; Yuan et al., 2015). We predicted that the effects of fentanyl, naltrexone, and the mixtures
would match the predicted results in Fig. 1 (right panel). Additionally, we predicted that the
maximal effects of fentanyl, naltrexone, and the mixtures could be used to generate efficacyeffect scales for quantification of both (1) MOR efficacy requirements for antinociception at 50
and 54°C, and (2) relative efficacies of the six MOR test ligands.

The overarching goal of this dissertation was to utilize the opioid combination medication
experimental approach in a nonhuman primate model of thermal nociception to evaluate two
putative MOR agonist adjuncts. Two experimental design features were common throughout
these studies. First, fixed-proportion mixtures were utilized when possible to model the clinical
application of opioid adjunct combination products. Second, behavioral selectivity was assessed
using an assay of schedule-controlled responding to enhance experimental rigor and provide
evidence that opioid plus adjunct mixtures were not due to behavioral sedation or impairment.
Our working hypothesis is that putative MOR agonist adjuncts should selectively enhance the
therapeutic effects of MOR agonist compared to undesirable MOR agonist effects. Finally, the
application of fixed-proportion opioid mixtures to principles of receptor theory was examined as
a method to quantitatively stratify MOR agonists based on in vivo efficacy.
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Chapter 2: Determining the utility of the NMDA receptor antagonists ketamine and MK-801 as
candidate adjuncts to MOR agonists in the selective production of anti-allodynia using doseaddition analysis in male rhesus monkeys.

INTRODUCTION
Pain states pose a major public health challenge in the United States and around the
world; one recent estimate suggest that over one-third of Americans reported pain symptoms
within the past three months (Nahin, 2015). Mu-opioid agonists, such as hydrocodone and
oxycodone, are increasingly being prescribed for pain management and from 2000 to 2010 there
was a 4-fold increase in opioid prescriptions (Comer et al., 2013). However, mu-opioid agonists
are limited in their clinical utility due to undesirable effects such as sedation and abuse liability.
One drug development approach may be to combine mu agonists with adjuncts targeting other
receptor systems to enhance the therapeutic effects (e.g. antinociception) and/or attenuate
undesirable effects (e.g. sedation) (Dietis et al., 2009).
One receptor system that might be a biological target of interest is the glutamatergic
system. Three lines of evidence support the evaluation of N-Methyl-D-Aspartate (NMDA)
receptor antagonists as adjunctions to mu-opioid agonists. First, anatomical studies have
demonstrated the presence of NMDA receptors at both the spinal level within the dorsal horn and
supraspinal level in nociceptive pathways (Rodriguez-Munoz et al., 2012; Bourbia et al., 2014).
Second, NMDA receptor antagonists, such as ketamine and dizocilpine (MK-801), produce
antinociception in some, but not all, preclinical models of pain utilizing mice (Malec et al.,
2008), rats (Hillhouse and Negus, 2016), and monkeys (France et al., 1989; Allen and Dykstra,
2001; Banks et al., 2010a) as research subjects. Lastly, preclinical studies in rodents have
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suggested these NMDA receptor antagonists may also enhance the antiallodynic and
antihyperalgesic effects mu agonists in rodents depending upon the noxious stimulus (Holtman Jr
et al., 2008; Pascual et al., 2010). Furthermore, these preclinical studies are supported by some
clinical evidence suggesting that although ketamine has undesirable effects, it also may serve as
a useful adjunct to mu agonists under certain clinical conditions (for review and recent metaanalysis, see (McGuinness et al., 2011; Lee and Lee, 2016)). Overall, both preclinical and
clinical studies support the further consideration of NMDA antagonists as adjuncts to mu
agonists.
The goal of the present study was to determine whether mu-opioid agonist efficacy was a
determinant of opioid/NMDA interactions in male rhesus macaques using previously described
procedures for opioid interaction assessment (Stevenson et al., 2003; Banks et al., 2010a).
Antiallodynic interactions were assessed using an assay of capsaicin-induced thermal allodynia
for two main reasons. First, ketamine may have anti-inflammatory properties (De Kock et al.,
2013; Wang et al., 2013), attenuates capsaicin-induced allodynia in humans (Park et al., 1995)
and monkeys (Butelman et al., 2003), and we have previously shown that ketamine alone does
not produce antinociception in monkeys using a warm water tail-withdrawal procedure (Banks et
al., 2010a). Thus, one potential reason for the lack of a synergistic interaction between ketamine
and fentanyl in our previous monkey study (Banks et al., 2010a) could be the preclinical
nociception procedure. For example, delta-opioid agonist and mu agonist antinociceptive
interactions were found to be synergistic using a strict thermal noxious stimulus (i.e. warm water
tail-withdrawal), but additive under thermal allodynia (i.e. capsaicin-induced thermal allodynia)
conditions (Stevenson et al., 2003; Banks et al., 2010a; Negus et al., 2012). Second,
opioid/NMDA antagonist interactions have not been previously assessed in preclinical allodynia
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models using nonhuman primates as research subjects and under experimental conditions using
fixed-proportion mixtures and dose-addition analysis. Drug interactions were also evaluated in
an assay of schedule-controlled responding for the following two reasons. First, nalbuphine,
oxycodone, ketamine, and MK-801 alone produced dose-dependent effects in this procedure, and
data from this procedure could be used to quantify the relative potencies of fixed-proportions in
drug mixtures if one of the drugs (e.g. MK-801) was inactive in the assay of capsaicin-induced
thermal allodynia. Second, drug or drug mixture effects on schedule-controlled responding
provide one dependent measure of behavioral depression that may confound measures of
antiallodynia in pain-stimulated behaviors (i.e. tail withdrawal). Therefore, potency comparisons
of drug or drug mixture effects in assays of allodynia and schedule-controlled responding may
provide an experimental index of therapeutic effect selectivity. Based on the preclinical
literature, we hypothesized that NMDA antagonists would selectively enhance mu agonistinduced antiallodynia vs. mu agonist-induced rate suppression.

METHODS
Subjects:
A total of 7 adult male rhesus macaques (Macaca mulatta) of either Indian or Chinese
origin and weighing between 10-14 kg served as subjects. Three monkeys were used in studies of
schedule-controlled responding, and 4 monkeys were used in studies of capsaicin-induced
thermal allodynia. All animals had prior experimental histories consisting of opioids, cocaine,
and NMDA antagonist exposure. The diet consisted of laboratory monkey chow (#5049, Purina,
Framingham, MA), and was supplemented daily with fresh fruits and/or nuts. Monkeys were
individually housed with free access to water under a 12-h light/12-h dark cycle (lights on from
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6:00 AM until 6:00 PM). The facility was licensed by the United States Department of
Agriculture and accredited by AAALAC International. Both research and enrichment protocols
were approved by the Institutional Animal Care and Use Committee and in accordance with the
8th edition of the Guide for the Care and Use of Laboratory Animals (Council, 2011).
Environmental enrichment included: music, movies, puzzle feeders, and chew toys. Furthermore,
monkeys were afforded opportunities to interact socially using olfactory and auditory cues;
mirrors provided visual interaction.

Behavioral Procedures
Assay of Capsaicin-Induced Thermal Allodynia
Monkeys were seated in acrylic restraint chairs as described previously (Banks et al.,
2010b). The monkey’s tail was shaved at least once a week 10-12 cm from the tip upward, and
baseline tail-withdrawal latencies were measured from water heated to 38, 42, 46, and 50 °C.
The maximal latency was 20 s, and if the monkey had not withdrawn its tail within 20 s, the
experimenter removed the tail, and a latency of 20 s was assigned. Using this procedure,
temperature-effect functions were determined in each monkey at the beginning of the behavioral
session, and the highest temperature that failed to elicit a tail withdrawal was determined (i.e.,
the highest temperature to produce a tail-withdrawal latency of 20 s). Water heated to this
temperature then served as the thermal stimulus for subsequent allodynia studies during that
session. Allodynia was elicited by topical capsaicin application (0.3 mL of either 1.22M (n=2) or
2.44M (n=2) capsaicin) as described previously (Butelman et al., 2004; Banks et al., 2010b).
After baseline tail-withdrawal latency determinations, the subject’s tail was wiped with an
alcohol pad and a topical capsaicin patch was prepared as described below (see Drugs); the patch
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was applied to a region ~ 5 cm from the bottom of the tail for 5 min. After 5 min, the patch was
removed and tail-withdrawal latencies were redetermined using the thermal stimulus identified
from the baseline temperature-effect function. Initially, nalbuphine (0.032-0.32 mg/kg),
oxycodone (0.01-0.32 mg/kg), ketamine (0.32-1.8 mg/kg), and MK-801 (0.0032-0.056 mg/kg)
were tested alone and each dose was tested once. A single drug or drug mixture dose was
administered 5 min before topical capsaicin administration and the time course of drug or drug
mixture effects on tail-withdrawal latencies was determined over the course of 60 min in 15-min
intervals starting 30 min post-drug or drug mixture administration. Subsequently three mixtures
(1:0.33, 1:1, and 1:3 mu agonist/NMDA antagonist) of nalbuphine or oxycodone in combination
with ketamine or oxycodone in combination with MK-801 were examined such that the
intermediate proportion was 1:1 mu agonist/NMDA antagonist, and 3-fold lower and higher
proportions were also determined. The fixed proportions for nalbuphine/ketamine and
oxycodone/ketamine were based on the relative potencies of these compounds in the assay of
capsaicin-induced thermal allodynia because all compounds were behaviorally active. However,
fixed proportions of oxycodone/MK-801 were based on the relative potencies of these
compounds in the assay of schedule-controlled responding because MK-801 did not produce >
50% maximum possible effect (MPE) in all monkeys up to doses that produced undesirable
effects. Testing occurred twice weekly on Tuesdays and Fridays.

Assay of Schedule-Controlled Responding
Experiments were conducted in each monkey’s housing chamber which also served as the
experimental chamber as previously described (Banks et al., 2010a). A custom-fabricated
operant response panel and a food pellet dispenser (Med Associates, ENV-203-1000, St. Albans,
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VT) were attached to the front of the housing chamber. Panels were operated under a MED-PC
interface and programmed with an IBM computer using MEDSTATE Notation (MED
Associates). All behavioral training sessions were comprised of five 30-min cycles for a total
session duration of 150 min. Two components were incorporated into each cycle. The first
component was a 25-min time-out period during which responding was recorded, but had no
scheduled consequences. The second component was a 5-min response period during which the
right key was illuminated red, and subjects could respond under a fixed-ratio 30 (FR30) schedule
of food pellet presentation. The response component terminated immediately and lights were
extinguished if a subject earned the maximum of 10 pellets prior to completion of the 5-min
period. All monkeys were trained until rates of responding were ≥ 1.0 response/s during all 5
cycles for 7 consecutive days (data not shown).
Behavioral sessions were conducted 5 days per week. Test sessions were usually
conducted on Tuesdays and Fridays, and training sessions were conducted on Mondays,
Wednesdays, and Thursdays. Subjects were eligible for participation in test sessions if rates of
operant responding were ≥ 1.0 response/s on training days that preceded test days. On test days,
test compounds were administered intramuscular (IM) using a cumulative dosing procedure, in
which doses of the test drug or drug mixture were administered at the beginning of the 25-min
time-out period, and each dose increased the total cumulative dose by one-fourth or one-half log
units in 30-min intervals.
Initially, dose-effect functions were determined for nalbuphine (0.032-1.8 mg/kg),
oxycodone (0.01- 1.0 mg/kg), ketamine (0.1-3.2 mg/kg) or MK-801 (0.0032-0.032 mg/kg) alone,
and each drug was tested twice. Subsequently, three mixtures of ketamine in combination with
nalbuphine or oxycodone were examined. In addition, three mixtures of MK-801 and oxycodone
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were also examined. All drug mixtures were studied across a range of three fixed-proportions
(1:0.33, 1:1, and 1:3 mu agonist/NMDA antagonist) such that the intermediate proportion was
1:1 mu agonist/NMDA antagonist, and 3-fold lower and higher proportions were also
determined. Each mixture was tested once, and mixtures were evaluated twice a week. All drugs
and drug mixtures were tested up to doses that decreased responding >50% of the preceding
training day’s response rate.
In addition, drug interactions can also be influence by their relative time courses. The
relative time courses of ED80 nalbuphine, oxycodone, ketamine, and MK-801 doses were
compared in the assay of schedule-controlled responding. Either saline, or a single nalbuphine
(1.65 mg/kg), oxycodone (0.37 mg/kg), ketamine (1.41 mg/kg), or MK-801 (0.039 mg/kg) dose
was administered, and 5 min response periods were initiated 10, 30, 100, and 300 min after drug
administration.

Data Analysis
For the assay of capsaicin-induced thermal allodynia, raw tail-withdrawal latencies were
converted to a percent maximum possible effect (%MPE). %MPE was defined as {(Test latency
– Control latency) ÷ (20 – Control latency)*100} where “test latency” was the average latency
over the 60-min test session and “control latency” was the average latency over a 60-min control
session during which vehicle was administered. For the assay of schedule-controlled responding,
raw rates of operant responding from each test cycle were converted to a percent control rate
using the average response rate from all 5 cycles from the previous training day in that monkey.
The effective dose (ED50) that produced 50%MPE or 50% decrease in control rate of
responding was determined for each mu agonist alone and in combination with either ketamine
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or MK-801 in each monkey for both assays. ED50 values were determined by interpolation when
only two data points were available (one below and one above the 50% effect) or by linear
regression when at least 3 data points were available on the linear portion of the dose-effect
function. Individual ED50 values were subsequently averaged to yield mean ED50 values and
95% confidence limits. In addition, potency ratios were calculated for each individual subject by
dividing the control ED50 value by the test ED50 value. These potency ratios were then averaged
to yield group mean potency ratios and 95% confidence limits. Potency ratios were considered
statistically significant if the 95% confidence limits of the group mean potency ratio did not
include 1.
To evaluate drug interactions within an assay, both graphical and statistical approaches to
dose-addition analysis were utilized as described previously (Stevenson et al., 2003; Banks et al.,
2010a). Graphically, data for each drug and drug mixture were plotted as isobolograms at the
50% effect level. An isobologram plotted one drug dose ± SEM in a mixture as a function of the
other drug dose ± SEM in a mixture at the overall mixture dose that produced 50% effect.
Statistical evaluation of drug interactions was accomplished by comparing the experimentally
determined ED50 value for each mixture (Zmix) with the predicted additivity ED50 value (Zadd)
as previously described (Tallarida, 2000; Tallarida, 2016). Zadd values were calculated for each
individual monkey using the equation: 𝑍𝑎𝑑𝑑 = 𝑓𝐴 + 1 − 𝑓 𝐵, where Α was the mu agonist
alone ED50 value, Β was the NMDA antagonist alone ED50 value, and ƒ was a fractional
multiplier of Α in the computation of the additive total dose. The experiments described in this
study tested mixtures that yielded values of ƒ=0.25, ƒ=0.5, and ƒ=0.75, were ƒ is related to the
proportion of the mu agonist in a mixture per the equation ρA=ƒ/Zadd. When mixtures were
studied in the assay of capsaicin-induced thermal allodynia, where MK-801 was inactive, the

36
additivity hypothesis predicts the inactive drug should not contribute to the mixture effect. Thus,
the equation for Zadd = Α/ρΑ. Zmix was calculated for each monkey as the total drug dose that
decreased rates of responding to 50% of control or produced 50% MPE. Group mean Zmix and
Zadd values were significantly different if the 95% confidence intervals did not overlap.

Drugs
(−)-Oxycodone HCl was provided by the National Institute on Drug Abuse Drug Supply
Program (Bethesda, MD). Racemic ketamine HCl was purchased from a commercial vendor as
KetaVed© (Vedco, St. Joseph, MO). (−)-Nalbuphine HCl was provided by Dr. Kenner Rice
(Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on
Alcohol Abuse and Alcoholism, Bethesda, MD). (+)-MK-801 hydrogen maleate was purchased
from a commercial vendor (Sigma-Aldrich, St. Louis, MO). NMDA antagonists, mu-opioid
agonists, and combination fixed proportions were dissolved in sterile water. Capsaicin (M2028;
Sigma-Aldrich) was dissolved in a mixture of 70% ethanol (Pharmaco-AAPER, Brookfield, CT)
and 30% sterile water no more than 30 minutes before use. Dissolved capsaicin was applied
transdermally via an adhesive bandage measuring 2.5 x 8.3 cm (Band-Aid, Johnson and Johnson,
New Brunswick, NJ). All drug doses were expressed as the salt forms listed above and
administered intramuscularly into the thigh.

RESULTS
Mu-opioid agonist and ketamine interactions
Assay of capsaicin-induced thermal allodynia
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The highest thermal stimulus that failed to elicit a tail-withdrawal response before
capsaicin treatment was 42°C in two monkeys and 46°C in the other two monkeys throughout
the study. Transdermal capsaicin application produced allodynia as indicated by reduced mean ±
SEM tail withdrawal latencies at these temperatures to 2.5 ± 0.9 s, 2.0 ± 1.3 s, 2.5 ± 1.9 s, and
1.5 ± 1.0 s at 15, 30, 45, and 60 min after capsaicin treatment, respectively. Nalbuphine,
oxycodone, and ketamine produced dose-dependent antiallodynia (Figure 1A). The ED50 values
and 95% confidence limits for each drug alone are shown in Tables 1 and 2. Based on these ED50
values, three mixtures of nalbuphine + ketamine (1:3.3, 1:10, and 1:33 nalbuphine/ketamine) and
oxycodone + ketamine (1:3.6, 1:10.7, and 1:32.1 oxycodone/ketamine) were examined. The dose
ranges examined for each nalbuphine + ketamine mixture were 0.01-0.1 mg/kg nalbuphine
(1:3.3), 0.01-0.1 mg/kg nalbuphine (1:10), and 0.01-0.056 mg/kg nalbuphine (1:33). The dose
ranges examined for each oxycodone + ketamine mixture were 0.01-0.1 mg/kg oxycodone
(1:3.6), 0.01-0.056 mg/kg oxycodone (1:10.7), and 0.0032-0.056 mg/kg oxycodone (1:32.1).
Larger doses were not examined due to the emergence of undesirable effects (e.g. muscle tone
loss) that impaired the monkey’s ability to maintain a sufficiently sternal posture in the chair.
Tables 1 and 2 also show the ED50 values for each drug in each mixture, and Table 3 shows the
predicted Zadd and experimentally determined Zmix values for nalbuphine/ketamine and
oxycodone/ketamine mixtures. The dose-effect functions for nalbuphine/ketamine and
oxycodone/ketamine mixtures are shown in Figure panels 2A and 3A, respectively.
Isobolograms for both drug mixtures are shown in Figure panels 2C and 3C. Combining
ketamine with either nalbuphine or oxycodone did not significantly alter the potency of either mu
agonist to produce antiallodynia; however, ED50 values were only able to be determined in 2 out
of 3 monkeys with the 1:10 and 1:33 nalbuphine/ketamine mixtures and the 1:32.1
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oxycodone/ketamine mixture. For nalbuphine and ketamine mixtures, the 1:3.3 and 1:10
mixtures produced additive effects. In the two monkeys that an ED50 value could be determined
with the 1:33 nalbuphine/ketamine mixture, the effects were sub-additive. All oxycodone and
ketamine mixtures produced antiallodynia effects consistent with additivity.

Assay of Schedule-Controlled Responding
The average ± SEM control response rate throughout the entire study was 2.5 ± 0.1
responses/s. Nalbuphine, oxycodone, and ketamine dose-dependently decreased rates of
responding (Figure 1B). The ED50 values and 95% confidence limits for each drug are shown in
Tables 1 and 2. Based on the relative potencies in the assay of capsaicin-induced thermal
allodynia, the same three mixtures of nalbuphine + ketamine (1:3.3, 1:10, and 1:33
nalbuphine/ketamine) and oxycodone + ketamine (1:3.6, 1:10.7, and 1:32.1
oxycodone/ketamine) were examined. The dose ranges examined for each nalbuphine +
ketamine mixture were 0.01-1 mg/kg nalbuphine (1:3.3), 0.01-0.32 mg/kg nalbuphine (1:10), and
0.0032-0.1 mg/kg nalbuphine (1:33). The dose ranges examined for each oxycodone + ketamine
mixture were 0.01-1 mg/kg oxycodone (1:3.6), 0.01-0.32 mg/kg oxycodone (1:10.7), and
0.0032-0.1 mg/kg oxycodone (1:32.1). The dose-effect functions for nalbuphine/ketamine and
oxycodone/ketamine mixtures are shown in Figure panels 2B and 3B, respectively. Isobolograms
are shown in Figure panels 2D and 3D. Tables 1 and 2 also show the ED50 values for each drug
in each mixture, and Table 3 shows the predicted Zadd and experimentally determined Zmix
values for the nalbuphine/ketamine and oxycodone/ketamine mixtures, respectively. Increasing
fixed proportions of ketamine enhanced the potency of nalbuphine to decrease rates of
responding as demonstrated by the 95% confidence limits for the potency ratios not including
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one. Dose-addition analysis demonstrated that all nalbuphine/ketamine mixtures produced
additive effects. For oxycodone and ketamine mixtures, fixed proportions of 1:10.7 and 1:32.1
increased the potency of oxycodone to decrease rates of responding compared to oxycodone
alone. Dose-addition analysis demonstrated the 1:3.6 and 1:10.7 oxycodone/ketamine mixtures
produced sub-additive effects; whereas the 1:32.1 oxycodone/ketamine mixture produced
additive effects.

Oxycodone and MK-801 interactions
Assay of capsaicin-induced thermal allodynia
Oxycodone alone produced dose-dependent antiallodynia, whereas MK-801 produced a
maximum %MPE of 22.7 ± 17.8 at a dose of 0.032 mg/kg (Figure 1A). The ED50 values and
95% confidence limits for oxycodone alone and each drug in the drug mixture are shown in
Table 4. Because MK-801 produced > 50%MPE in only one subject, the relative potencies were
based on the ED50 values in the assay of schedule-controlled responding (below). The dose
ranges examined for all oxycodone + MK-801 mixtures were 0.01-0.32 mg/kg oxycodone and
larger doses were not examined due to the emergence of undesirable effects (e.g. muscle tone
loss) that impaired the monkey’s ability to maintain a sufficiently sternal posture in the chair.
The dose-effect functions for oxycodone/MK-801 mixtures are shown in Figure panels 4A. The
isobologram for the three oxycodone + MK-801 mixtures are shown in Figure 4C. Increasing
fixed proportions of MK-801 did not significantly alter the potency of oxycodone to produce
antiallodynia (Table 4). Table 5 shows the predicted Zadd and experimentally determined Zmix
values for the oxycodone/MK-801 mixtures. The 1:0.028 and 1:0.085 oxycodone/MK-801
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mixture produced effects consistent with additivity, whereas the 1:0.25 oxycodone/MK-801
mixtures produced significant sub-additive effects.

Assay of Schedule-Controlled Responding
Oxycodone and MK-801 alone produced dose-dependent decreases in rates of responding
(Figure 1B). The ED50 values and 95% confidence limits for each drug are shown in Table 4, and
based on the relative potencies, three mixtures of oxycodone + MK-801 (1:0.028, 1:0.085, and
1:0.25 oxycodone/MK-801) were examined. The dose ranges examined for each oxycodone +
MK-801 mixture were 0.01-1 mg/kg oxycodone (1:0.028), 0.01-0.56 mg/kg oxycodone
(1:0.085), and 0.01-0.32 mg/kg oxycodone (1:0.25). The dose-effect functions for
oxycodone/MK-801 mixtures are shown in Figure panel 4B. The isobologram for all three
oxycodone + MK-801 mixtures are shown in Figure 4D. Fixed proportions (0.028 and 0.25) of
MK-801 significantly enhanced the potency of oxycodone to decrease rates of responding (Table
4). Table 5 shows the predicted Zadd and experimentally determined Zmix values for each drug
mixture. All oxycodone and MK-801 mixtures produced effects consistent with additivity.

Time Course Analysis
Figure 5 shows the time course of nalbuphine, oxycodone, ketamine, and MK-801 in the
assay of schedule-controlled responding. Two-way repeated-measures analysis of variance
demonstrated a significant main effect of time (F3,6=164.9, p<0.0001), drug (F4,8=28.9,
p<0.0001), and drug × time interaction (F12,24=8.5, p<0.0001). All four drugs produced
significant and peak rate-decreasing effects within 10-30 min post administration. MK-801 did
produce rate-decreasing effects that were significantly different from oxycodone and ketamine,
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but not nalbuphine, at the 30-min time point. Nalbuphine and MK-801 produced rate-decreasing
effects that persisted to at least 100 min and were significantly longer than oxycodone and
ketamine.

DISCUSSION
This study assessed interactions between the noncompetitive NMDA antagonists racemic
ketamine and (+)-MK-801 and the low-efficacy mu agonist nalbuphine and the moderateefficacy mu agonist oxycodone in assays of capsaicin-induced thermal allodynia and schedulecontrolled responding in rhesus monkeys. The main finding was that both racemic ketamine and
(+)-MK-801 failed to enhance the antiallodynic effects of nalbuphine and oxycodone.
Furthermore, ketamine selectively enhanced the potency of both nalbuphine and oxycodone to
produce rate suppression. Overall, these preclinical results in monkeys do not support further
consideration of noncompetitive NMDA antagonists as clinically useful adjuncts to mu-opioid
agonists for the treatment of pain states associated with thermal hypersensitivity.

Effects of Mu agonists and NMDA antagonists alone
Consistent with previous studies in rodents (Emery et al., 2017), nonhuman primates
(Banks et al., 2010b; Negus et al., 2012), and humans (Watson and Babul, 1998; Hoeben et al.,
2012), both nalbuphine and oxycodone produced dose-dependent antiallodynia. Both nalbuphine
and oxycodone dose-dependently decreased rates of operant responding and these nalbuphine
results were consistent with previous nonhuman primate studies examining the rate-suppressant
effects of mu-opioid agonists (Stevenson et al., 2003; Banks et al., 2010a). Furthermore, the
present results extended these previous findings by determining the antiallodynic and rate-
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suppressant effects of the mu agonist oxycodone in nonhuman primates. Oxycodone was
approximately 4 to 5-fold more potent to produce antiallodynia vs. rate suppression.
Although both ketamine and MK-801 produced dose-dependent decreases in rates of
responding, only ketamine produced dose-dependent antiallodynia in the assay of capsaicininduced thermal allodynia. Both the rate-suppressant and antiallodynia effects of ketamine in the
present study are consistent with previous results in rhesus monkeys (Butelman et al., 2003;
Banks et al., 2010a). Furthermore, the present MK-801 results are consistent with a previous
study in mice (Gewehr et al., 2011). In apparent contrast to the present results demonstrating
MK-801 failed to produce antiallodynia, previous nonhuman primate studies have reported
antiallodynic effects of MK-801 in an assay of capsaicin-induced thermal allodynia (Butelman et
al., 2003) and antinociceptive effects in an assay of thermal nociception (France et al., 1989).
However, the anti-allodynic effects of MK-801 were only present at a low thermal stimulus of
38°C and MK-801 antiallodynic effects were more variable when the thermal stimulus was
increased to 42°C (Butelman et al., 2003). In the present study, the baseline thermal intensities
before capsaicin application were 42°C for two monkeys and 46°C for the other two monkeys. In
the one monkey that did show an antiallodynic effect of MK-801, the baseline thermal intensity
was 42°C. Another explanation for the differential ketamine and MK-801 results in the assay of
capsaicin-induced thermal allodynia could be due to ketamine interacting with other receptor
systems than NMDA. For example, racemic ketamine has been shown to have similar affinity for
opioid receptors compared to the NMDA channel binding site (Hustveit et al., 1995). Overall, the
general consistency of the present results with the published literature provided an empirical
foundation to determine mu agonist and NMDA antagonist interactions.
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Antiallodynia interactions
No fixed proportion of either NMDA antagonist selectively enhanced the antiallodynic
effects of nalbuphine or oxycodone. The present additive antiallodynic results are consistent with
ketamine and alfentanil analgesic interactions in humans using intradermal capsaicin (Sethna et
al., 1998). Furthermore, the present additive or sub-additive interactions are consistent with and
extend previous findings from our laboratory (Banks et al., 2010a) and others (Hoffmann et al.,
2003; Craft and Lee, 2005; Edwards et al., 2007; Haghparast et al., 2007; Pascual et al., 2010;
Lilius et al., 2015) examining NMDA antagonist and mu-opioid agonist combinations in other
preclinical assays of nociception, including allodynia. However, the present results may appear
in contrast to previous studies in rodents demonstrating that NMDA antagonists enhance the
antiallodynic/antihyperalgesic effects of mu agonists (Holtman Jr et al., 2008; Pascual et al.,
2010). There are two potential explanations for the differential results between the present study
and these previous studies reporting an enhanced antinociceptive effect of the mu agonist.
First, drug interactions are not only dependent upon the relative dose, but also time
course of each drug in a mixture. Thus, differences in mu agonist and NMDA antagonist time
course could have influenced drug interactions when conducting fixed proportion interaction
studies. This explanation seems unlikely for the following two reasons. First, peak rate
decreasing effects were at 10 min for nalbuphine, oxycodone, and ketamine and 30 min for MK801 in the assay of schedule-controlled responding (Figure 5). Furthermore, all drugs produced
significant rate-decreasing effects for at least 30 min, which was within the pretreatment time
range used in assay of schedule-controlled responding. Second, statistical analyses did not
demonstrate a significant main effect of time in the assay of capsaicin-induced thermal allodynia
for any drug alone or drug mixture. Overall, these results suggest that modest differences in time
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course between the drugs do not fully explain the absence of a selective NMDA antagonist
enhancement of mu agonist antiallodynia.
Second, behavioral selectivity to produce antiallodynia vs. suppression of operant
responding may also explain the differential results. Pain-stimulated behaviors, such as tail
withdrawal, are highly susceptible to false positive results due to drug-induced motor
impairment. In paclitaxel-treated rats, ketamine and morphine combinations produced an
enhanced anti-thermal hyperalgesic effect, but no interaction on mechanical allodynia and no
assessment of motor activity (Pascual et al., 2010). In a rat chronic constriction nerve injury
model, the ketamine metabolite norketamine enhanced the antiallodynic and antihyperalgesic
effects of morphine at dose combinations that did not significantly alter behavior in a rotorod or
locomotor activity procedure (Holtman Jr et al., 2008). Moreover, a recent meta-analysis of
ketamine and opioid use for pain reduction found that ketamine did not generally enhance pain
relief produced by opioids (only 1 out of 6 showed an enhancement) and in fact, may enhance
some undesirable neurological and psychological undesirable effects (Lee and Lee, 2016).
Overall, the literature suggests that NMDA antagonists may selectively enhance the
antiallodynic/antihyperalgesic effects of mu agonists over a narrow range of experimental
conditions that depend upon not only the research subject species, but also the type of noxious
stimulus and underlying physiological state.

Comparison with other mu agonist interactions
The present mu agonist and NMDA antagonist interaction results can be compared to
results that have determined fixed-proportion drug mixtures of other drug classes in combination
with mu agonists under similar procedures. Two will be mentioned. First, the serotonin and
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norepinephrine uptake inhibitor clomipramine selectively enhanced both the antiallodynic and
antinociceptive vs. rate-suppressant effects of nalbuphine in monkeys (Banks et al., 2010b).
Second, the delta-opioid agonist SNC80 has also selectively enhanced the antiallodynic and
antinociceptive vs. rate-suppressant effects of nalbuphine in monkeys (Stevenson et al., 2003;
Negus et al., 2012). In contrast, fixed proportions of NMDA antagonists and mu agonists have
thus far failed to produce a selective enhancement of antinociception vs. rate suppression in both
assays of capsaicin-induced thermal allodynia (present results) and warm water tail withdrawal
(Banks et al., 2010a) and. Overall, this literature highlights the utility of the behavioral
procedures described in the present study to examine mu agonist and other drug class
interactions in the development of mu opioid adjuncts for the clinical treatment of various pain
states.
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FIGURE LEGENDS
Figure 1: Potency of nalbuphine, oxycodone, ketamine, and MK-801 to produce anti-allodynia
in an assay of capsaicin-induced thermal allodynia (Panel A; n=3-4) and decrease rates of
responding in an assay of schedule-controlled responding (Panel B; n=3) in rhesus monkeys. Top
abscissae: unit intramuscular (IM) drug dose in milligrams per kilogram (log scale). Top
ordinate: percent maximum possible effect. Bottom abscissae: cumulative intramuscular (IM)
drug dose in milligrams per kilogram (log scale). Bottom ordinate: percent control rate of
responding. Each point shows mean ± SEM for 3-4 monkeys.

Figure 2: Effects of the mu-opioid agonist nalbuphine alone or in combination with the
noncompetitive NMDA antagonist ketamine on capsaicin-induced thermal allodynia (left panels)
and rates of schedule-controlled responding (right panels). Top panels show dose-effect
functions for nalbuphine alone or in combination with ketamine and bottom panels show
isobolograms at the ED50 effect level for nalbuphine or ketamine alone or as part of a mixture.
Top abscissae: unit nalbuphine dose (left panel) or cumulative nalbuphine dose (right panel) in
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom
panels show isobolograms at the ED50 effect level for nalbuphine or ketamine alone or as part of
a mixture. Bottom abscissae: ED50 values for nalbuphine alone or in a mixture in milligrams per
kilogram (linear scale). Bottom ordinates: ED50 values for ketamine alone or in a mixture in
milligrams per kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys,
except when noted by the number in parentheses. This denotes an experimental condition where
an ED50 value could not be determined in all subjects tested.
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Figure 3: Effects of the mu-opioid agonist oxycodone alone or in combination with the
noncompetitive NMDA antagonist ketamine on capsaicin-induced thermal allodynia (left panels)
and rates of schedule-controlled responding (right panels). Top panels show dose-effect
functions for oxycodone alone or in combination with ketamine and bottom panels show
isobolograms at the ED50 effect level for oxycodone or ketamine alone or as part of a mixture.
Top abscissae: unit oxycodone dose (left panel) or cumulative oxycodone dose (right panel) in
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom
panels show isobolograms at the ED50 effect level for oxycodone or ketamine alone or as part of
a mixture. Bottom abscissae: ED50 values for oxycodone alone or in a mixture in milligrams per
kilogram (linear scale). Bottom ordinates: ED50 values for ketamine alone or in a mixture in
milligrams per kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys.
Asterisk indicates that the mixture produced a sub-additive effect in the assay of schedulecontrolled responding as determined by dose-addition analysis (see Table 3).

Figure 4: Effects of the mu-opioid agonist oxycodone alone or in combination with the
noncompetitive NMDA antagonist MK-801 on capsaicin-induced thermal allodynia (left panels)
and rates of schedule-controlled responding (right panels). Top panels show dose-effect
functions for oxycodone alone or in combination with MK-801 and bottom panels show
isobolograms at the ED50 effect level for oxycodone or MK-801 alone or as part of a mixture.
Top abscissae: unit oxycodone dose (left panel) or cumulative oxycodone dose (right panel) in
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom
abscissae: ED50 values for oxycodone alone or in a mixture in milligrams per kilogram (linear
scale). Bottom ordinates: ED50 values for MK-801 alone or in a mixture in milligrams per
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kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys. Asterisk indicates
that the mixture produced a sub-additive effect in the assay of capsaicin-induced thermal
allodynia as determined by dose-addition analysis (see Table 5).

Figure 5: Time course of ED80 doses of nalbuphine (1.65 mg/kg), oxycodone (0.37 mg/kg),
ketamine (1.41 mg/kg), and MK-801 (0.039 mg/kg) in an assay of schedule controlled
responding in rhesus monkeys. Abscissa: time in min. post administration. Ordinate: percent
control rate of responding. Each point represents the mean ± SEM of three rhesus monkeys.
Filled symbols denote statistical significance (p<0.05) compared to vehicle.
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Table 1: ED50 values (95% confidence limits) for nalbuphine, oxycodone, and ketamine alone
or in combination in assays of capsaicin-induced thermal allodynia and scheduled-controlled
responding in rhesus monkeys. Numbers in parentheses denote the number of subjects
contributing to the ED50 value if less than the total number of monkeys tested (n=3) and the >
symbol denotes a drug mixture for which an ED50 value could not be determined in all subjects
tested.
Drug or drug mixture

Nalbuphine

Potency Ratio

Ketamine

ED50 (95% CL)

(95% CL)

ED50 (95% CL)

Capsaicin-induced thermal
allodynia
Nalbuphine Alone
Ketamine Alone
1:3.3 Nalbuphine/Ketamine

0.05 (0, 0.36)

-

0.03 (0.02, 0.04)

0.53 (0.31, 0.91)
1.38 (-2.91,

0.11 (0.08, 0.15)

5.66)
1:10 Nalbuphine/Ketamine (n=2)

> 0.06 (0.03, 0.1)

> 0.65 (0.1, 4.15)

1:33 Nalbuphine/Ketamine (n=2)

> 0.04 (0, 0.17)

> 1.29 (0.07,
24.12)

Schedule-controlled responding
Nalbuphine Alone
Ketamine Alone
1:3.3 Nalbuphine/Ketamine

0.7 (0.25, 1.96)

-

0.18 (0.09, 0.35)

0.86 (0.70, 1.06)
0.28 (-0.06,

0.59 (0.30, 1.16)

0.63)a
1:10 Nalbuphine/Ketamine

0.12 (0.08, 0.17)

0.21 (-0.24,

1.15 (0.80, 1.67)
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0.66)a
1:33 Nalbuphine/Ketamine

0.04 (0.02, 0.06)

0.07 (-0.07,

1.12 (0.71, 1.79)

0.20)a

a

Potency shifts were considered statistically significant if the 95% confidence limits of the

potency ratios did not include 1.
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Table 2: ED50 values (95% confidence limits) for oxycodone and ketamine alone or in
combination assays of capsaicin-induced thermal allodynia and scheduled-controlled responding
and in rhesus monkeys. Numbers in parentheses denote the number of subjects contributing to
the Zmix or Zadd values if less than the total number of monkeys tested (n=3) and the > symbol
denotes a drug mixture for which an ED50 value could not be determined in all subjects tested.
Drug or drug mixture

Oxycodone

Potency Ratio

Ketamine

ED50 (95% CL)

(95% CL)

ED50 (95% CL)

Capsaicin-induced thermal
allodynia
Oxycodone Alone
Ketamine Alone

0.05 (0.01, 0.2)
-

0.53 (0.31, 0.91)

1:3.6 Oxycodone/Ketamine

0.03 (0.01, 0.17) 0.61 (-0.56, 1.78)

0.11 (0.05, 0.25)

1:10.7 Oxycodone/Ketamine

0.04 (0.02, 0.07) 0.56 (0.11, 1.02)

0.38 (0.28, 0.51)

1:32.1 Oxycodone/Ketamine

> 0.03 (0, 0.21)

> 0.82 (0.28, 2.39)

(n=2)
Schedule-controlled responding
Oxycodone Alone
Ketamine Alone

0.25 (0.17, 0.37)
-

0.86 (0.70, 1.06)

1:3.6 Oxycodone/Ketamine

0.21 (0.12, 0.36) 0.83 (0.44, 1.23)

0.75 (0.44, 1.28)

1:10.7 Oxycodone/Ketamine

0.12 (0.08, 0.16) 0.47 (0.17, 0.76) a 1.24 (0.88, 1.75)

1:32.1 Oxycodone/Ketamine

0.04 (0.02, 0.07) 0.17 (0, 0.34) a

1.29 (0.72, 2.31)
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a

Potency shifts were considered statistically significant if the 95% confidence limits of the

potency ratios did not include 1.

58
Table 3: Experimentally determined Zmix values and predicted Zadd values (95% confidence
limits) for mixtures of nalbuphine or oxycodone and ketamine in assays of capsaicin-induced
thermal allodynia and schedule-controlled responding in rhesus monkeys. Numbers in
parentheses denote the number of subjects contributing to the Zmix or Zadd values if less than
the total number of monkeys tested (n=3) and denote a drug mixture for which an ED50 value
could not be determined.
Drug or drug mixture

Zmix

Zadd

Capsaicin-induced thermal allodynia
1:3.3 Nalbuphine/Ketamine

0.15 (0.13, 0.17)

0.19 (0.11, 0.34)

1:10 Nalbuphine/Ketamine (n=2)

0.71 (0.53, 0.95)

0.33 (0.18, 0.61)

1:33 Nalbuphine Ketamine (n=2)

1.33 (0.85, 2.1) a

0.43 (0.26, 0.71)

1:3.6 Oxycodone/Ketamine

0.15 (0.07, 0.32)

0.17 (0.15, 0.20)

1:10.7 Oxycodone/Ketamine

0.41 (0.31, 0.55)

0.25 (0.18, 0.35)

1:32.1 Oxycodone/Ketamine (n=2)

0.84 (0.29, 2.45)

0.41 (0.28, 0.61)

1:3.3 Nalbuphine/Ketamine

0.77 (0.40, 1.51)

0.80 (0.45, 1.45)

1:10 Nalbuphine/Ketamine

1.27 (0.88, 1.84)

0.85 (0.64, 1.14)

1:33 Nalbuphine/Ketamine

1.61 (0.73, 1.85)

0.87 (0.79, 0.95)

1:3.6 Oxycodone/Ketamine

0.96 (0.57, 1.63) a

0.42 (0.39, 0.44)

1:10.7 Oxycodone/Ketamine

1.36 (0.96, 1.91) a

0.57 (0.52, 0.62)

1:32.1 Oxycodone/Ketamine

1.33 (0.74, 2.38)

0.71 (0.61, 0.84)

Schedule-controlled responding
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a

Denotes Zmix confidence limits do not overlap with Zadd confidence limits: Zmix larger than

Zadd indicating sub-additivity.
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Table 4: ED50 values (95% confidence limits) for oxycodone and MK-801 alone or in
combination assays of scheduled-controlled responding and capsaicin-induced thermal allodynia
in rhesus monkeys.
Drug or drug mixture

Oxycodone

Potency Ratio

MK-801

ED50 (95% CL)

(95% CL)

ED50 (95% CL)

Capsaicin-induced thermal
allodynia
Oxycodone Alone
MK-801 Alone
1:0.028 Oxycodone/MK-801

1:0.085 Oxycodone/MK-801

0.05 (0.04, 0.06)

-

0.13 (0.06, 0.3)

0.13 (0.05, 0.32)

Inactive
2.64 (-1.69,

0.004 (0.002,

6.98)

0.008)

2.09 (-2.71, 6.9)

0.011 (0.004,
0.027)

1:0.25 Oxycodone/MK-801

0.17 (0.07, 0.4)

2.37 (-2.12,

0.041 (0.017,

6.87)

0.099)

Schedule-controlled responding
Oxycodone Alone
MK-801 Alone
1:0.028 Oxycodone/MK-801

1:0.085 Oxycodone/MK-801

0.27 (0.15, 0.51)

-

0.23 (0.12, 0.47)

0.20 (0.12, 0.33)

0.02 (0.02, 0.03)
0.86 (0.75,

0.01 (0.003,

0.98) a

0.013)

0.74 (0.35,

0.02 (0.01, 0.03)

1.14)
1:0.25 Oxycodone/MK-801

0.12 (0.05, 0.28)

0.45 (0.19,

0.03 (0.01, 0.07)
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0.71) a

a

Potency shifts were considered statistically significant if the 95% confidence limits of the

potency ratios did not include 1.
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Table 5: Experimentally determined Zmix values and predicted Zadd values (95% confidence
limits) for mixtures of oxycodone and MK-801 in assays of capsaicin-induced thermal allodynia
and schedule-controlled responding in rhesus monkeys.
Drug or drug mixture

Zmix

Zadd

Capsaicin-induced thermal allodynia
1:0.028 Oxycodone/MK-801

0.14 (0.08, 0.23)

0.06 (0.05, 0.08)

1:0.085 Oxycodone/MK-801

0.14 (0.08, 0.24)

0.06 (0.05, 0.08)

1:0.25 Oxycodone/MK-801

0.21 (0.12, 0.35) a

0.07 (0.06, 0.09)

1:0.028 Oxycodone/MK-801

0.24 (0.12, 0.48)

0.21 (0.12, 0.39)

1:0.085 Oxycodone/MK-801

0.22 (0.13, 0.36)

0.15 (0.09, 0.26)

1:0.25 oxycodone/MK-801

0.15 (0.07, 0.35)

0.09 (0.06, 0.14)

Schedule-controlled responding

a

Denotes Zmix confidence limits do not overlap with Zadd confidence limits: Zmix larger than

Zadd indicating sub-additivity.
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Chapter 3: Identifying potential pharmacological determinants of the antinociceptive interaction
between the NOP receptor agonist adjunct, Ro 64-6198, and MOR agonists in male rhesus
monkeys.

1. INTRODUCTION
Pain management remains a significant public health issue in the United States
(Ballantyne et al, 2017). Mu-opioid receptor agonists (e.g. oxycodone) are one of the most
effective pharmacological tools available to clinicians for the treatment of pain (Dowell and
Haegerich, 2016). However, the clinical utility of mu-opioid agonists is severely limited by a
number of undesirable effects including respiratory depression and sedation. One approach to
enhance the clinical utility of mu-opioid agonists may be to combine them with other compounds
that act through different receptor mechanisms (Di Cesare Mannelli et al., 2015; Dietis et al.,
2009; Gunther et al., 2017).
One potential receptor system that might function as a useful mu-opioid agonist adjunct
is the nociceptin opioid peptide (NOP) system. Two lines of evidence support potential
interactions between mu-opioid and NOP receptors. First, NOP receptors are colocalized with
mu-opioid receptors in both spinal and brain regions involved in nociceptive signaling pathways
(for review, see Toll et al. 2016). Second, preclinical studies have reported species difference in
the antinociceptive effects of the selective high-efficacy NOP agonist Ro 64-6198 (Jenck et al.,
2000). For example, systemic Ro 64-6198 produced antinociception in monkeys (Ko et al.,
2009), but not rodents (Reiss et al., 2008). Further highlighting potential species differences,
systemic combinations of Ro 64-6198 and a mu-opioid agonist produced additive antinociceptive
effects in mice (Reiss et al., 2008), but synergistic antinociceptive effects in rhesus monkeys
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(Cremeans et al., 2012). Overall, this literature supports further evaluation of NOP and muopioid agonist interactions.
Previous studies examining mu-opioid agonist antinociceptive interactions with other
receptor systems suggest that one important determinant of these interactions may be MOR
agonist efficacy (Banks et al., 2010b; Maguire and France, 2014; Negus et al., 2009). However,
the degree to which mu-opioid agonist efficacy is a determinant of NOP agonist interactions is
unknown. Therefore, the aim of the present study was to determine the role of mu-opioid ligand
efficacy in antinociceptive interactions with the NOP agonist Ro 64-6198 in rhesus monkeys
using previously described procedures (Banks et al., 2010b; Stevenson et al., 2003).
Antinociceptive interactions between Ro 64-6198 and six mu-opioid ligands (17cyclopropylmethyl- 3,14β-dihyroxy-4,5α-epoxy-6α-[(3 ́-isoquinolyl)acetamindo]morphinan
(NAQ), buprenorphine, nalbuphine, morphine, oxycodone, and methadone) that vary in agoniststimulated GTPγS binding from lowest to highest (Selley et al., 1998; Thompson et al., 2004;
Zaidi et al., 2013) and in their in vivo effectiveness to produce antinociception (Cornelissen et
al., 2018a) were investigated. For comparison, Ro 64-6198 interactions were also investigated
with the selective high efficacy kappa-opioid receptor agonist nalfurafine. Nalfurafine is not a
clinically-approved analgesic and fails to produce antinociception under conditions that
dissociate antinociception from behavioral sedation (Endoh et al., 2001; Lazenka et al., 2018).
Drug interactions were also examined in an assay of schedule-controlled responding in a
different cohort of monkeys to assess behavioral selectivity to produce antinociception vs. rate
suppression. If NOP agonists are to be considered as candidate mu-opioid agonist adjuncts, then
we would hypothesize that Ro 64-6198 would robustly and selectively enhance the
antinociceptive vs. rate-suppressant effects of mu-opioid agonists.
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2. MATERIALS AND METHODS
2.1 Subjects
A total of seven middle-aged adult (10-18 years old) male rhesus macaques (Macaca
mulatta) of either Indian or Chinese origin and weighing between 10-14 kg served as subjects.
Four monkeys served as subjects in the assay of thermal nociception, and three monkeys served
as subjects in the assay of schedule-controlled responding. These sample sizes have been
sufficient to detect mu-opioid agonist interactions in previous publications (Banks et al., 2010a;
Banks et al., 2010b; Maguire and France, 2014; Schwienteck et al., 2018; Stevenson et al.,
2003). All monkeys had experimental histories of opioid, monoamine transporter ligand, and Nmethyl D-aspartate antagonist exposure. Diet was comprised of laboratory monkey chow (#5049,
Purina, Framingham, MA) and supplemented with fresh fruits, vegetables, and nuts. All subjects
were housed individually and had ad lib water access while in the housing chamber. A 12h
light/dark cycle (lights on from 6:00 AM to 6:00 PM) was in effect. Housing facilities were
licensed by the United States Department of Agriculture and accredited by AAALAC
International. The VCU Institutional Animal Care and Use Committee approved all research and
enrichment protocols in accordance with the 2011 Guide for the Care and Use of Laboratory
Animals.

2.2 Assay of Thermal Nociception
Monkeys were trained to sit comfortably in an acrylic restraint chair using the pole-andcollar technique such that their tails hung freely. The subject’s tail was shaved 10-12 cm from
the distal end weekly and immersed in a thermal container of warm water. If the subject did not
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remove its tail by 20 s, the experimenter removed the tail and a latency of 20 s was assigned. A
stopwatch was utilized to record tail-withdrawal latencies. During each 15-min cycle, tailwithdrawal latencies were recorded from water warmed to 38°C, 50°C, and 54°C and the order
of warmed water presentations was counterbalanced between successive cycles. Baseline tailwithdrawal latencies at all three thermal intensities were determined in each daily test session
before drug administration. Test sessions continued only if tail-withdrawal latencies from 38°C
water did not occur before the 20 s cutoff. This criterion was met in every monkey during every
test session. Time course test sessions consisted of a single drug dose administered
intramuscularly (IM) and tail withdrawal latencies were re-determined at 10, 30, and 100 min
post-drug administration. Cumulative dose test sessions consisted of four to five 15-minute
cycles composed of a 10-minute drug pretreatment phase and a 5-min testing phase. Drugs were
administered IM at the start of each 15-min cycle, and each drug dose increased the total
cumulative dose by one-fourth or one-half log units. Tail-withdrawal latencies were redetermined during the 5-min testing phase as described above.
Initially, the time course of (−)-Ro 64-6198 (0.1 and 0.32 mg/kg) and SB-612111 (0.32
mg/kg) were singly determined. Following these initial Ro 64-6198 time-course experiments,
two additional experiments were conducted. First, the effectiveness of Ro 64-6198 to alter the
antinociceptive effects of 6 mu-opioid ligands and the kappa-opioid agonist nalfurafine was
determined. Cumulative dose-effect functions for NAQ (0.1-3.2 mg/kg), buprenorphine (0.032-1
mg/kg), nalbuphine (0.032-3.2 mg/kg), morphine (0.1-10 mg/kg), oxycodone (0.01-1 mg/kg),
methadone (0.1-5.6 mg/kg), and nalfurafine (0.0001-0.01 mg/kg) were determined following a
30-min pretreatment of 0.1 mg/kg Ro 64-6198 or vehicle. Mu-opioid ligands were tested up to
doses that produced maximal antinociception, undesirable effects such as respiratory depression,
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or reached solubility limits. Nalfurafine was tested up to doses that produced emesis. These
experiments were generally conducted twice per week, except for studies with buprenorphine,
nalbuphine, and nalfurafine, which were separated by at least 6 days to allow dissipation of longacting drug effects and/or to minimize potential effects of antinociceptive tolerance. Ro 64-6198
test sessions were also separated by at least 7 days. Second, potency, time course, and
antagonism of Ro 64-6198 enhancement of nalbuphine-induced antinociception were determined
in three of the four monkeys used for the mu-opioid ligand and Ro 64-6198 interactions
described above. One monkey was removed from this set of experiments due to health issues
unrelated to the study. These experiments were also separated by at least 7 days. The
experimenter was not blinded to drug or dose conditions due to potential animal health issues
when evaluating novel drug interactions consistent with our previous publications (Banks et al.,
2010a; Banks et al., 2010b; Cornelissen et al., 2018a). Ro 64-6198 and vehicle pretreatments
were counterbalanced between opioid ligands, but pretreatments were consistent across all
monkeys.

2.3 Assay of Schedule-Controlled Responding
Experiments were conducted in each monkey’s housing chamber, which also served as
the experimental chamber as previously described (Banks et al., 2010b). A custom-fabricated
operant response panel and a food pellet dispenser (Med Associates, ENV-203-1000, St. Albans,
VT) were attached to the front of the housing chamber. Panels were operated under a MED-PC
interface and programmed with a Windows-based computer using MEDSTATE Notation (MED
Associates). Training sessions were composed of five 15-min cycles for a total session duration
of 75 min. Two components were incorporated into each cycle. The first component was a 10-
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min time-out period during which responses had no scheduled consequences. The second
component was a 5-min response period during which the right key was transilluminated red,
and subjects could respond under a fixed-ratio 30 (FR30) schedule of food pellet presentation. If
a subject earned the maximum of 10 pellets prior to completion of the 5-min period, the response
component was terminated, stimulus lights were extinguished, and further responses resulted in
no consequences. All monkeys were trained until rates of responding were ≥ 1.0 response/s
during all 5 cycles for 7 consecutive days (data not shown).
Behavioral sessions were conducted 5 days per week. Training sessions were conducted
on Mondays, Wednesdays, and Thursdays, and test sessions were conducted on Tuesdays and
Fridays. Subjects were eligible for participation in test sessions if rates of operant responding
were ≥ 1.0 response/s on training days that preceded test days. On test days, test compounds
were administered IM using the same cumulative dosing procedure described above in the assay
of thermal nociception. All drugs and pretreatment combinations were tested up to doses that
either decreased responding >70% of the preceding training day’s average response rate or
reached solubility limits. Individual test sessions lasted for 3 to 6 cycles depending on individual
subject behavior and treatment condition.
Initially, the potency and time course of vehicle, (−)-Ro 64-6198 (0.1-0.32 mg/kg), and
SB- 612111 (0.32 mg/kg) were determined. Additionally, the effectiveness of SB-612111 to
antagonize the rate-decreasing effects of Ro 64-6198 was evaluated. Subsequently, Ro 64-6198
interactions with the same opioid ligands evaluated in the assay of thermal nociception were
determined. Cumulative dose-effect functions for NAQ (0.1-10 mg/kg), buprenorphine (0.0323.2 mg/kg), nalbuphine (0.032-1 mg/kg), morphine (0.1-5.6 mg/kg), oxycodone (0.01-1.0
mg/kg), methadone (0.1-3.2 mg/kg), and nalfurafine (0.0001-0.0032 mg/kg), were determined
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following a 30-min pretreatment of 0.1 mg/kg Ro 64-6198 or vehicle. These experiments were
generally conducted twice per week, except for studies with buprenorphine, nalbuphine, and
nalfurafine, which were separated by at least 7 days to allow dissipation of long-acting drug
effects and/or to minimize potential tolerance to the rate-decreasing effects of low efficacy muopioid ligands. Ro 64-6198 test sessions were also separated by at least 7 days. Ro 64-6198 and
vehicle pretreatments were counterbalanced between opioid ligands, but pretreatments were
consistent across all monkeys.

2.4 Data Analysis
For the assay of thermal nociception, tail-withdrawal latencies (in sec) were converted to
percent maximal possible effect (%MPE). %MPE was defined as {(Test latency – Control
latency) ÷ (20 – Control Latency) * 100} where “test latency” was the latency in response to
either 50°C or 54°C at each dose during the cumulative dosing procedure, and “control latency”
was the latency in response to either 50°C or 54°C taken during the baseline period prior to drug
administration. Statistical analysis of all %MPE data was conducted using a repeated-measures
two-way ANOVA with either time or pretreatment and opioid ligand dose as the main factors
(all factors repeated measures). A Sidak or Tukey post-hoc test, as appropriate, followed all
significant interactions. Significance was set a priori at the 95% confidence level.
For the assay of schedule-controlled responding, rates of operant responding
(responses/sec) during each test cycle were converted to percent control rate using the average
rate of responding of the 5 cycles from the individual monkey’s previous training session.
Statistical analysis of all % control data was conducted using a repeated-measures two-way
ANOVA with either time or pretreatment and opioid ligand dose as the main factors (all factors
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repeated measures). A Sidak or Tukey post-hoc test, as appropriate, followed all significant
interactions.
In addition, the effective dose (ED50) that produced either 50%MPE or 50% reduction in
control rates of responding was determined for each mu-opioid ligand and nalfurafine following
0.1 mg/kg Ro 64-6198 or vehicle pretreatment. ED50 values were determined by interpolation
when only 2 data points were available (one below and one >50% effect) or by linear regression
when at least 3 data points on the linear portion of the dose-effect function were available as
previously described (Banks et al., 2010b; Cornelissen et al., 2018a; Cornelissen et al., 2018b;
Stevenson et al., 2003). Individual ED50 values were subsequently averaged to yield group mean
ED50 values and 95% confidence intervals using the Student’s T distribution (confidence.t
equation in Microsoft Excel for Mac, Version 16.9, Microsoft, Redmond, WA).

2.5 Drugs
(±)-Methadone HCl and (±)-buprenorphine HCl were purchased from a commercial
supplier (Spectrum Chemicals, Gardena, CA). (−)-Oxycodone HCl, (−)-morphine sulfate, (−)nalfurafine HCl, (−)-Ro 64-6198 HCl, and SB-612111 HCl were supplied by the National
Institute on Drug Abuse Drug Supply Program (Bethesda, MD). (−)-Nalbuphine HCl was
supplied by Dr. Kenner Rice (Drug Design and Synthesis Section, National Institute on Drug
Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD). NAQ HCl was
synthesized as previously described (Li et al., 2009) and supplied by Drs. Samuel Obeng and
Yan Zhang. Buprenorphine, nalbuphine, oxycodone, morphine, methadone, and nalfurafine were
dissolved in sterile water. (−)-Ro 64-6198 was dissolved in a solution of 1:4:5 Tween 80
(Spectrum Chemicals, Gardena, CA) to dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
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MO) to sterile water. SB-612111 was dissolved in a solution of 4:6 DMSO to sterile water. NAQ
was dissolved in a solution of 3:7 DMSO to sterile water. All drug doses were administered
intramuscularly and expressed as the salt forms listed above.

3. RESULTS
3.1 Effects of Ro 64-6198 alone
Average ± S.E.M. baseline tail withdrawal latencies for Ro 64-6198 alone and in
combination with various mu-opioid ligand experiments were 1.0 ± 0.4 s at 50°C and 0.7 ± 0.1 s
at 54°C. Average control rates of responding across all experiments was 2.5 ± 0.4 responses/s.
Fig. 1 shows the potency and time course of Ro 64-6198 alone to produce antinociception
(panels A and B) and rate-suppression (panel C). Up to 0.32 mg/kg, Ro 64-6198 did not produce
significant antinociception with a maximum %MPE of 9.4 ± 7.4 and 1.1 ± 0.8 at 50 and 54°C,
respectively. In contrast, Ro 64-6198 produced dose- and time-dependent decreases in rates of
responding with maximal effects at 100 min following 0.32 mg/kg administration (treatment:
F4,8=16.2, P<0.05; time: F3,6=18.8, P<0.05; interaction: F12,24=2.9, P<0.05). The rate-decreasing
effects of Ro 64-6198 were blocked by the NOP antagonist SB-612111 at a dose (0.32 mg/kg)
that had no effect on rates of responding alone. Larger Ro 64-6198 doses (1.0 mg/kg) were
evaluated, but required prompt SB-612111 administration due to the emergence of undesirable
effects including loss of muscle tone and slowed respiratory rate.

3.2 Effects of Ro 64-6198 pretreatment on mu-opioid ligand-induced antinociception
Fig. 2 shows the antinociceptive effects of NAQ, buprenorphine, nalbuphine, morphine,
oxycodone, and methadone following either vehicle or 0.1 mg/kg Ro 64-6198 pretreatment.
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Buprenorphine, nalbuphine, morphine, oxycodone, and methadone produced dose-dependent
antinociception at 50°C under vehicle conditions and the corresponding ED50 values for each
mu-opioid agonist are reported in Table 1. NAQ produced a group mean ± S.E.M. maximum
%MPE of 4.9±5.1 at 50°C (Fig. 2, panel A). Supplemental Fig. 1 also shows the antinociceptive
effects of these same mu-opioid ligands alone at a higher thermal intensity (54°C). Only
morphine, oxycodone, and methadone produced > 50%MPE at 54°C and the corresponding ED50
values are reported in Supplemental Table 1. NAQ, buprenorphine, and nalbuphine produced a
maximum %MPE of 1.1±1.9, 9.3±6.9, and 37.2±7.3 at 54°C, respectively (Supplemental Table
1).
Pretreatment with a Ro 64-6198 dose (0.1 mg/kg) that was ineffective alone significantly
enhanced the antinociceptive effects of buprenorphine (dose: F2,6= 29.4, P<0.05; pretreatment:
F1,3=17.4, P<0.05; interaction: F2,6=17.0, P<0.05), nalbuphine (dose: F4,12= 489, P<0.05;
pretreatment: F1,3=79.3, P<0.05; interaction: F4,12=19.8, P<0.05), and methadone (dose:
F4,12=56.6, P<0.05; interaction: F4,12=4.2, P<0.05) at 50°C (Fig. 2). The corresponding ED50
values of each mu-opioid agonist following Ro 64-6198 pretreatment are also reported in Table
1. Post-hoc power analyses indicated the morphine (power=0.65) and oxycodone (power=0.67)
experiments were underpowered to detect a significant interaction between Ro 64-6198 and these
two mu-opioid agonists. At the 54°C thermal stimulus, Ro 64-6198 pretreatment also
significantly enhanced the antinociceptive effects of methadone (methadone dose: F4,12=657,
P<0.05; pretreatment: F1,3=146.4, P<0.05; interaction: F4,12= 65.1, P<0.05). The corresponding
ED50 values for methadone and the other mu-opioid agonists at 54°C are also reported in
Supplemental Table 1.
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3.3 Effects of Ro 64-6198 pretreatment on mu-opioid ligand-induced rate-suppression
Fig. 3 shows the effects of NAQ, buprenorphine, nalbuphine, morphine, oxycodone, and
methadone on rates of responding following either vehicle or 0.1 mg/kg Ro 64-6198
pretreatment. NAQ and buprenorphine alone did not significantly alter rates of responding up to
the largest doses tested and maximal rate-decreasing effects (mean ± S.E.M.) were 87.4 ± 27.9%
and 64.9 ± 20.8% control, respectively (Fig. 3). Larger NAQ and buprenorphine doses could not
be examined due to solubility limits. However, NAQ and buprenorphine were tested up to doses
that antagonized the antinociceptive effects of other mu-opioid agonists (Cornelissen et al.,
2018a; Walker et al., 1995). Nalbuphine, morphine, oxycodone, and methadone alone all
produced dose-dependent decreases in rates of responding and the corresponding ED50 values are
shown in Table 1. Ro 64-6198 pretreatment did not enhance the effectiveness of NAQ or
buprenorphine to alter rates of responding (Fig. 3). Ro 64-6198 pretreatment also did not
enhance the potency of nalbuphine, morphine, oxycodone, or methadone to decrease rates of
responding as denoted by overlapping confidence limits for ED50 values (Table 1).

3.4 Effects of Ro 64-6198 pretreatment on nalfurafine-induced antinociception and ratesuppression
Fig. 4 shows the antinociceptive (A) and rate-altering (B) effects of nalfurafine following
either vehicle or 0.1 mg/kg Ro 64-6198 pretreatment. Nalfurafine alone failed to produce
antinociception up to the highest dose tested with maximal effects (mean ± S.E.M.) of 9.1 ± 10.7
% and 6.8 ± 2.9 % at 50 and 54°C, respectively (Fig. 4 panels A and B). Ro 64-6198 enhanced
the antinociceptive effects of nalfurafine at 50°C (nalfurafine dose: F4,8=4.7, P<0.05; interaction:
F4,8= 4.8, P<0.05) (Fig. 4 panel A). Nalfurafine alone produced dose- and time- dependent
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decreases in rates of responding and the corresponding ED50 values are shown in Table 1. Time
course of nalfurafine rate-decreasing effects are shown in Supplemental Fig. 2. Ro 64-6198
pretreatment attenuated the effectiveness of cumulative 0.001 mg/kg nalfurafine to decrease rates
of responding (nalfurafine dose: F3,6=11.7, P<0.05; interaction: F3,6= 8.9, P<0.05). Ro 64-6198
did not alter nalfurafine potency to decrease rates of responding (Table 1).

3.5 Potency, time course, and antagonism of Ro 64-6198 enhancement of nalbuphine
antinociception
Fig. 5 shows the potency (A), time course (B), and sensitivity to NOP antagonism (C) of
Ro 64-6198 enhancement of nalbuphine antinociception at 50°C. For these experiments, group
mean ± S.E.M. baseline tail withdrawal latencies were 0.8 ± 0.3 s at 50°C and 0.8 ± 0.2 s at
54°C. There was no significant effect of Ro 64-6198 on nalbuphine effects at 54°C (data not
shown). Similar to results in Fig. 2, 0.1 mg/kg Ro 64-6198, but not 0.032 mg/kg, enhanced
nalbuphine antinociception (nalbuphine dose: F4,8=39.3, P<0.05; Ro 64-6198 dose: F2,4= 12.1,
P<0.05; interaction: F8,16= 8.3, P<0.05) (Fig. 5 panel A). In addition, only the 30-min
pretreatment time was sufficient for Ro 64-6198 to enhance the antinociceptive effects of
nalbuphine (time: F3,6=6.3, P<0.05; nalbuphine dose: F4,8=61.3, P<0.05; interaction: F12,24=6.8,
P<0.05) (Fig. 5 panel B). Finally, Ro 64-6198 enhancement of nalbuphine antinociception was
blocked by the NOP antagonist SB-612111 (nalbuphine dose: F4,8=53.5, P<0.05; pretreatment:
F3,6=11.7, P=0.05; interaction: F12,24=9.3, P<0.05) (Fig. 5 panel C). SB-612111 (0.32 mg/kg)
pretreatment also significantly attenuated the antinociceptive effects of the 0.32 mg/kg
cumulative nalbuphine dose (Fig. 5 panel C).

75
4. DISCUSSION
4.1 Conclusions
The present study determined whether mu-opioid ligand efficacy was a determinant of
antinociceptive interactions with the NOP agonist (−)-Ro 64-6198 in rhesus monkeys. There
were three main findings. First, both Ro 64-6198 and nalfurafine were more potent to decrease
rates of responding than produce antinociception. Second, Ro 64-6198 enhanced the
antinociceptive potency of buprenorphine, nalbuphine, and methadone suggesting that mu-opioid
agonist efficacy was not a determinant of mu-opioid and NOP agonist interactions. Despite, Ro
64-6198 and mu-opioid agonist interactions displaying some degree of behavioral selectivity, Ro
64-6198 enhancement of mu-agonist antinociception occurred under a narrow range of
experimental conditions. Lastly, NOP agonist interactions were not selective for mu-opioid
agonists because Ro 64-6198 also enhanced the antinociceptive effects of the kappa-opioid
agonist nalfurafine. Collectively, these results dampen enthusiasm for NOP agonists as candidate
“opioid-sparing” adjuncts.

4.2 Effects of Ro 64-6198, mu-opioid agonists, and nalfurafine alone
The mu-opioid agonists buprenorphine, nalbuphine, morphine, oxycodone, and
methadone produced dose- and noxious stimulus- dependent antinociception consistent with the
extant literature (Cornelissen et al., 2018a; Gatch et al., 1998; Maguire and France, 2014; Walker
et al., 1993). Nalfurafine failed to produce antinociception up to a 3-fold larger dose than doses
that suppressed rates of responding. Although nalfurafine has been previously shown to produce
antinociception in a warm water tail-withdrawal procedure in monkeys (Endoh et al., 2001; Ko
and Naughton, 2009), nalfurafine-induced antinociception in these previous studies occurred at
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doses larger than those that maximally decreased rates of responding in the present study. The
NOP agonist Ro 64-6198 also did not produce antinociception up to doses that significantly
decreased rates of responding. These results were consistent with a previous monkey study
(Saccone et al., 2016), but inconsistent with other monkey studies (Cremeans et al., 2012; Ko et
al., 2009; Podlesnik et al., 2011). Reasons for the inconsistent NOP agonist antinociceptive
effects in monkeys are not entirely clear and highlight the importance of evaluating candidate
analgesics across a broad range of experimental conditions. One potential explanation for the
differential Ro 64-6198 antinociceptive results could be related to the experimental and
pharmacological histories of the monkeys. For example, monkeys in the Ko, et al (2009) study
had not been exposed to any opioid ligands for at least one month prior whereas monkeys in the
present study had a more extensive and recent opioid ligand history (Cornelissen et al., 2018a;
Cornelissen et al., 2018b). Thus, one interpretation could be that NOP agonists produce
antinociception in opioid-naïve or minimally opioid-experienced primates. Although opioid
ligand history did not impact the antinociceptive effects of mu-opioid ligands alone in the present
study, the degree to which opioid ligand exposure may alter the antinociceptive effects of NOP
agonists remains to be empirically determined.
The opioid agonists nalbuphine, morphine, oxycodone, and methadone decreased rates of
responding consistent with the extant literature (Banks et al., 2010b; Downs, 1979; Stevenson et
al., 2003). The present results extend these findings to the KOR agonist nalfurafine. NAQ failed
to significantly alter rates of responding in the present study. Previous studies have shown that
NAQ decreases rates of food-maintained responding (Siemian et al., 2016) and to a lesser extent,
electrical brain stimulation-maintained responding (Altarifi et al., 2015) in rats suggesting
potential species difference in NAQ effectiveness to decrease operant behavior. Buprenorphine
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also failed to significantly alter rates of responding and these results were consistent with
previous buprenorphine results in male monkeys (Negus et al., 2002). Ro 64-6198 ratedecreasing effects in the present study were consistent with previous Ro 64-6198 results in drug
discrimination (Saccone et al., 2016) and extended previous findings by determining Ro 64-6198
time course and sensitivity to SB-612111antagonism. Overall, the behavioral effects of the muopioid ligands and nalfurafine alone in the present study provide an empirical foundation for
examining interactions with Ro 64-6198.

4.3 Interactions between Ro 64-6198 and mu-opioid or kappa-opioid agonists
Ro 64-6198 significantly enhanced the antinociceptive effects of the mu-opioid ligands
buprenorphine, nalbuphine, and methadone as well as nalfurafine. The present results were
generally consistent with the direction, but not the magnitude, of previous mu-opioid and NOP
agonist antinociceptive interactions with buprenorphine (Cremeans et al., 2012) and morphine
(Hu et al., 2010; Ko and Naughton, 2009) in monkeys. NOP agonist enhancement of morphine
antinociception has also been reported in mice (Reiss et al., 2008) and rats (Jin‐Hua et al., 1997).
The present results extended upon these previous findings in three ways. First, NOP and muopioid agonist antinociceptive interactions were not dependent upon mu-opioid agonist efficacy.
Second, mu-opioid and NOP agonist antinociceptive interactions occurred under a narrow range
of experimental conditions such as dose and pretreatment time that suggests limited clinical
utility and effectiveness. Lastly, NOP agonist interactions were not selective for clinically
effective mu-opioid agonists because Ro 64-6198 also enhanced nalfurafine-induced
antinociception.
In contrast to mu-opioid and NOP agonist antinociceptive interactions, Ro 64-6198 did
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not significantly alter the rate-decreasing effects of any mu-opioid ligand examined. However,
Ro 64-6198 significantly attenuated the rate-decreasing effects of cumulative 0.001mg/kg
nalfurafine. These results suggest at least three main conclusions. First, Ro 64-6198
enhancement of mu-opioid agonist antinociception was not due to generalized behavioral
depression. However, one caveat is the Ro 64-6198 dose sufficient to enhance mu-opioid agonist
antinociception was only 3-fold smaller than the dose that significantly decreased rates of
responding. Thus, there may be a potential ceiling for the amount of NOP agonist in the
NOP/mu-opioid drug mixture. Second, the present results are consistent with and extend
previous NOP and mu-opioid agonist interactions to the mu-opioid agonist undesirable endpoint
behavioral depression. Previous studies have reported that NOP agonists do not enhance the
respiratory depressant, scratching-behavior, or reinforcing effects of mu-opioid agonists in
monkeys (Cremeans et al., 2012; Ko et al., 2009; Podlesnik et al., 2011). Third, although Ro 646198 attenuated the rate-decreasing effects of cumulative 0.001 mg/kg nalfurafine, nalfurafine
produced maximal rate-depression at similar doses irrespective of pretreatment. Overall, despite
mu-opioid and NOP agonist interactions displaying some degree of behavioral selectivity to
produce antinociception vs. rate suppression, the magnitude of these interactions were small and
not systematic across the various mu-opioid agonists.

4.4 Comparison to mu-opioid Agonist and Other Drug Interactions
Similar to mu-opioid and NOP agonist interactions, cannabinoid receptor agonists, deltaopioid agonists, serotonin uptake inhibitors and serotonin receptor agonists have also produced a
selective enhancement of mu-opioid agonist antinociception in rhesus monkeys (Banks et al.,
2010b; Gatch et al., 1998; Maguire and France, 2014; Negus et al., 2009; Stevenson et al., 2003).
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For example, the serotonin uptake inhibitor clomipramine enhanced the antinociceptive effects of
low efficacy mu-opioid agonists to a greater extent than high efficacy mu-opioid agonists (Banks
et al., 2010b; Gatch et al., 1998). In contrast, cannabinoid agonists enhanced the antinociceptive
effects of high efficacy mu-opioid agonists to a greater degree than low efficacy mu-opioid
agonists (Maguire and France, 2014). Furthermore, delta agonist enhancement of mu-opioid
agonist antinociception did not depend on mu-opioid agonist efficacy similar to the present NOP
agonist effects (Negus et al., 2009; Stevenson et al., 2003). Overall, this literature supports 1) the
inclusion of multiple dependent measures to assess behavioral selectivity in preclinical analgesia
drug development and 2) the systematic evaluation of behavioral interactions with mu-opioid
ligands that vary in efficacy.
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Legends for Figures
Fig 1: Time course of (−)-Ro 64-6198 and SB-612111 in assays of warm-water tail withdrawal
at 50°C (panel A) and 54°C (panel B) and schedule-controlled responding (panel C). Abscissae:
time in min after intramuscular Ro 64-6198 administration (log scale). Ordinates: percent
maximal possible effect (panels A and B) or percent control rate (panel C). All points represent
mean ± S.E.M. of 4 monkeys (except panel C where n=3). Asterisks denote significant (P<0.05)
difference from vehicle and 0.32 mg/kg (−)-Ro 64-6198 + 0.32 mg/kg SB-612111.

Fig 2: Antinociceptive effects (50°C) of NAQ, buprenorphine, nalbuphine, morphine,
oxycodone, and methadone following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment.
Abscissae: cumulative intramuscular mu-opioid ligand dose in milligrams per kilogram (log
scale). Ordinates: percent maximal possible effect (%MPE). All points represent mean ± S.E.M.
of 4 monkeys (except NAQ and morphine which is n=3). Asterisks denote significant (P<0.05)
difference from vehicle.

Fig 3: Rate-decreasing effects of NAQ, buprenorphine, nalbuphine, morphine, oxycodone, and
methadone following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment. Abscissae: cumulative
intramuscular mu-opioid ligand dose in milligrams per kilogram (log scale). Ordinates: percent
control rate. All points represent mean ± S.E.M. of 3 monkeys. Asterisks points denote
significant (P<0.05) difference from vehicle.

Fig 4: Antinociceptive (50°C; Panel A) and rate-decreasing (Panel B) effects of nalfurafine
following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment. Abscissae: cumulative
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intramuscular nalfurafine dose in milligrams per kilogram (log scale). Ordinates: percent
maximal possible effect (%MPE; panel A) or percent control rate of responding (panel B). Points
in panel A represent mean ± S.E.M. of 4 monkeys and panel B represent mean ± S.E.M. of 3
monkeys. Asterisks denote significant (P<0.05) difference from vehicle.

Fig 5: Antinociceptive effects (50°C) of nalbuphine following vehicle, (−)-Ro 64-6198, or SB
612111 pretreatment. Panel A shows effects of different Ro 64-6198 doses. Panel B shows
effects of different Ro 64-6198 pretreatment times. Panel C shows sensitivity to the NOP
antagonist SB-612111. Abscissae: cumulative intramuscular nalbuphine dose in milligrams per
kilogram (log scale). Ordinates: percent maximal possible effect (%MPE). All points represent
mean ± S.E.M. of 3 monkeys. Asterisks denote significant (P<0.05) difference from vehicle. #
denote significant difference (P<0.05) from Ro 64-6198 + SB-612111.
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Table 1: Opioid ligand ED50 values (95% confidence limits; CL) following vehicle or 0.1 mg/kg
(−)-Ro 64-6198 pretreatment in assays of thermal nociception (TW) and schedule-controlled
responding (SCR) in male rhesus monkeys. All values represent group mean ED50 values of 3
(SCR) or 4 (TW) monkeys unless otherwise denoted. a ED50 values are from three out of four
monkeys.
TW (50°C)

SCR

ED50 in mg/kg (95% CL)

ED50 in mg/kg (95% CL)

1.45 (1.01-1.89)

1.17 (0.66-1.68)

0.79 (0.52-1.06)

1.19 (0.63-1.74)

0.16 (0.02-0.30)

0.24 (0-1.14)

0.10 (0-0.45)

0.29 (0.13-0.45)

3.27 (0-7.76)

0.74 (0-1.89)

1.55 (0.86-2.25)

2.17 (0-6.10)

0.20 (0.04-0.36)

0.42 (0-1.19)

0.05 (0.05-0.07)

0.83 (0-2.88)

0.28 (0-0.62)a

NC

0.06 (0-0.30)

NC

NC

NC

NC

NC

NC

0.001 (0.001-0.002)

0.006 (0-0.012)

0.002 (0.001-0.014)

Opioid ligand
Methadone
+ Ro 64-6198
Oxycodone
+ Ro 64-6198
Morphine (n=3)
+ Ro 64-6198 (n=3)
Nalbuphine
+ Ro 64-6198
Buprenorphine
+ Ro 64-6198
NAQ
+ Ro 64-6198
Nalfurafine (n=3)
+ Ro 64-6198 (n=3)

NC: not calculable because no drug dose produced >50%MPE or decreased %Control rate below
50%
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Chapter 4: Expansion of the Furchgott equation for receptor theory by investigating the potential
for fixed-proportion mixtures of competitive MOR antagonist and MOR agonist to manipulate
antinociceptive efficacy in male rhesus monkeys.
INTRODUCTION
Pharmacodynamics is concerned with the affinity and efficacy of drugs at their receptor
targets. Drug affinity can be precisely measured with ligand binding techniques, but drug
efficacy to activate receptor signaling and produce downstream effects is a relative measure
dependent in part on the signaling pathway(s) and downstream effects under consideration, and
drug efficacies are typically described in relation to some standard high-efficacy ligand (Ruffolo,
1982; Kenakin, 2012). Although efficacy is challenging to measure, it is clearly relevant in drug
development. For example, mu-opioid receptor (MOR) ligands differ in their efficacy to activate
MOR-coupled signal transduction processes and produce MOR-mediated effects such as
analgesia and respiratory depression. Fentanyl has high MOR efficacy, and increasing fentanyl
doses can produce both antinociception and lethal respiratory depression (Gerak et al., 1994;
Banks et al., 2010a; Ding et al., 2016). At the other extreme of the efficacy continuum,
naltrexone has little or no MOR efficacy, produces no agonist effects, and functions as a
competitive reversible antagonist (Walker et al., 1994; Ko et al., 1998; Bowen et al.,
2002). Between these extremes are intermediate-efficacy MOR ligands like nalbuphine and
buprenorphine that produce submaximal stimulation of MOR signaling and a subset of agonist
effects that includes analgesia but only weak respiratory depression (Gerak et al., 1994; Pitts et
al., 1998; Kishioka et al., 2000). Experiments to investigate the expression and consequences of
ligand efficacy at MORs or other receptor targets can be useful both (a) to determine the efficacy
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required to produce different effects of interest, and (b) to evaluate relative efficacy of new
ligands as they are developed.
One common approach to efficacy evaluations relies on the use of irreversible antagonists
to evaluate the impact of reducing receptor number on expression of drug effects (Furchgott,
1966; Kenakin, 1993; Bergman et al., 2000). Efficacy requirements for different effects can be
estimated, because an irreversible antagonist will produce greater antagonism of effects with
high vs. low efficacy requirements (Zernig et al., 1997). Relative efficacies of different drugs can
be estimated, because an irreversible antagonist will produce greater antagonism of a low- vs.
high-efficacy agonist (Zimmerman et al., 1987; Walker et al., 1998). However, studies with
irreversible antagonists can be logistically challenging (e.g. due to the long duration of
antagonist effects), and irreversible antagonists are not available for many receptors of interest.
Decreases in receptor number can also be accomplished with genetic mutations, as in wild-type,
heterozygous, and homozygous receptor knockout animals (Grim et al., 2016), but the degree of
control over the magnitude of that decrease is limited. Receptor theory suggests an alternative,
more precise, and more flexible strategy to investigate efficacy using mixtures of competitive
agonists and antagonists. Figure 1A shows a theoretical dose-effect function for a high-efficacy
agonist administered alone or in the presence of increasing fixed doses of an antagonist. The
familiar result is an antagonist dose-dependent rightward shift in the agonist dose-effect curve
(Ko et al., 1998; Negus et al., 2003). Figure 1B shows theoretical effects using a different
experimental design, in which the agonist is administered in combination with fixed-proportional
doses of the antagonist, such that increasing agonist doses are administered in combination with
increasing antagonist doses. In this design, the antagonist is expected to produce proportiondependent downward shifts in the agonist dose-effect curve, and mixtures with decreasing
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agonist-to-antagonist proportions have decreasing apparent efficacies to activate the receptor.
This approach has two potential advantages relative to existing strategies. First, agonist-toantagonist proportion can be precisely manipulated to yield precise increments in efficacy.
Second, this approach could be applied to any receptor system for which a competitive agonist
and antagonist are available.
The goal of the present study was to test the utility of this approach using the competitive
MOR agonist fentanyl and antagonist naltrexone (Negus et al., 1993; Emmerson et al., 1994;
Walker et al., 1994; Emmerson et al., 1996). Effects of these drugs administered alone and in
fixed-proportion mixtures were determined in an assay of thermal nociception using two thermal
stimulus intensities (50 and 54°C warm water) and compared to effects produced by six other
MOR ligands shown previously to vary in their relative MOR efficacies in in vitro assays of
agonist-stimulated GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001;
Thompson et al., 2004; Yuan et al., 2015). We predicted that effects of fentanyl, naltrexone, and
the mixtures would match predicted results in Figure 1B. Additionally, we predicted that
maximal effects of fentanyl, naltrexone, and the mixtures could be used to generate efficacyeffect scales for quantification of both (a) MOR efficacy requirements for antinociception at 50
and 54°C, and (b) relative efficacies of the six MOR test ligands.

METHODS
Subjects
Four adult male rhesus macaques (Macaca mulatta) of either Indian or Chinese origin
and weighing between 10-14 kg served as subjects. All subjects had previous experimental
histories that included exposure to opioid ligands, monoaminergic transporter ligands, and N-
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methyl D-aspartate antagonists. Monkeys were fed a diet of laboratory biscuits (#5049, Purina,
Framingham, MA) supplemented with fresh fruits, vegetables, and nuts to maintain healthy,
stable body weights. Monkeys were individually housed in a temperature and humidity
controlled room that was maintained on a 12-h light/12-h dark cycle (lights on from 6:00 AM
until 6:00 PM). Water was available ad libitum in the housing chamber. The facility was licensed
by the United States Department of Agriculture and accredited by AAALAC International. Both
research and enrichment protocols were approved by the Institutional Animal Care and Use
Committee and in accordance with the 2011 Guide for the Care and Use of Laboratory Animals.
Environmental enrichment included: music, movies, puzzle feeders, and chew toys. Furthermore,
monkeys were afforded opportunities to interact socially using olfactory and auditory cues;
mirrors provided additional opportunities for visual interaction.

Assay of thermal nociception
Monkeys were trained to sit comfortably in an acrylic restraint chair using the pole-andcollar technique such that their tails hung freely. The subject’s tail was shaved 10-12 cm from
the distal end weekly and immersed in a thermal container of warm water. If the subject did not
remove its tail by 20 s, the tail was removed by the experimenter, and a latency of 20 s was
assigned. A stopwatch was utilized to record tail-withdrawal latencies. During each 15-min
cycle, tail-withdrawal latencies were recorded from water warmed to 38°C, 50°C, and 54°C and
the order of warmed water presentations varied between successive cycles. Baseline tailwithdrawal latencies at all three thermal intensities were determined in each daily test session
before drug administration. Test sessions continued only if tail-withdrawal latencies from 38°C
water did not occur before the 20-s cutoff. This criterion was met in every monkey during every
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test session. Cumulative dose test sessions consisted of four to six 15-minute cycles composed of
a 10-minute drug pretreatment phase and a 5-min testing phase. Drugs were administered
intramuscularly (IM) at the start of each 15-min cycle, and each drug dose increase the total
cumulative dose by one-fourth or one-half log units. Tail-withdrawal latencies were
redetermined during the 5-min testing phase as described above.
Initially, dose-effect functions were determined for fentanyl (0.001-0.056 mg/kg, IM) and
naltrexone (0.032-1 mg/kg, IM) alone and each dose-effect function was determined twice.
Subsequently, three fixed-proportion fentanyl and naltrexone mixtures were examined and each
cumulative dose-effect function was determined once. The proportions of each drug in the three
test mixtures were based on the published affinities (Kd) of fentanyl (1.48 nM) and naltrexone
(0.11 nM) at the mu-opioid receptor in rhesus monkey brain (Emmerson et al., 1994).
Specifically, the fixed-proportion of fentanyl to naltrexone for one mixture, denoted as the 1:1
mixture, was set to the proportion of their Kd values (1.48:0.11 = 1:0.074). Relative to the 1:1
mixture, the 3:1 fentanyl/naltrexone mixture had a three-fold higher proportion of fentanyl to
naltrexone (1:0.025), and the 1:3 fentanyl/naltrexone mixture had a three-fold lower proportion
of fentanyl to naltrexone (1:0.22). Mixtures were tested up to doses that produced maximal
antinociception, undesirable physiological effects such as respiratory depression, or antagonized
fentanyl effects in other studies. Experiments were generally conducted twice per week, usually
on Tuesdays and Fridays, with at least three days between test days.
Following these initial fentanyl/naltrexone fixed-proportion experiments, three additional
studies were conducted. First, for comparison to effects of the fentanyl/naltrexone mixtures,
cumulative dose-effect functions were determined for a series of six other MOR ligands that vary
from low to high in their efficacy at mu receptors as determined by in vitro assays of agonist-
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stimuluated GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001;
Thompson et al., 2004; Yuan et al., 2015): 17-cyclopropylmethyl-3,14β-dihyroxy-4,5α-epoxy6α-[(3´-isoquinolyl)acetamindo]morphinan (NAQ) (0.1-10 mg/kg, IM), buprenorphine (0.0323.2 mg/kg, IM), nalbuphine (0.032-3.2 mg/kg, IM), morphine (0.1-10 mg/kg, IM), oxycodone
(0.01-1 mg/kg, IM), and methadone (0.1-5.6 mg/kg, IM). Each dose-effect function was
determined once. Drugs were tested up to doses that produced maximal antinociception,
undesirable physiological effects such as respiratory depression, or antagonized fentanyl effects
in other studies. These experiments were generally conducted twice per week, except for studies
with buprenorphine, nalbuphine, and morphine, which were separated by at least 7 days to allow
dissipation of long-acting drug effects and/or to minimize potential effects of antinociceptive
tolerance. Second, receptor theory predicts that pretreatment with a low-efficacy agonist should
attenuate the potency, but not efficacy, of a higher efficacy agonist and thus shift the higher
efficacy agonist dose-effect function to the right. To test this hypothesis, fixed-dose pretreatment
experiments were conducted with naltrexone (0.0032-0.032 mg/kg, IM), NAQ (10 mg/kg, IM),
or 1:0.22 fentanyl/naltrexone mixture (0.032 mg/kg fentanyl + 0.007 mg/kg naltrexone, IM) to
cumulative fentanyl (0.001-1 mg/kg, IM), and each experiment was singly determined.
Naltrexone, NAQ, and the fentanyl/naltrexone mixture were administered 15 min before the first
fentanyl dose. Lastly, drug interactions can be influenced not only by the relative drug doses in a
mixture, but also by their relative time courses. Accordingly, the time course of 0.056 mg/kg
fentanyl was determined when combined with naltrexone as a 1:0.074 fixed-proportion mixture
for simultaneous administration of both drugs, and when the equivalent naltrexone dose (0.0041
mg/kg) in the 1:0.074 fentanyl/naltrexone mixture was administered 3 min before or 3 min after
0.056 mg/kg fentanyl alone. Tail-withdrawal latencies were redetermined 10, 30, and 100 min

94
after fentanyl administration unless emergence of respiratory depression required rescue with
additional naltrexone treatments. These experiments were generally conducted twice per week.

Data Analysis
Drug effects were expressed as %Maximum Possible Effect (%MPE) using the following
equation:
%𝑀𝑃𝐸 =

(𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑎𝑡𝑒𝑛𝑐𝑦)

(20 − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑎𝑡𝑒𝑛𝑐𝑦) ∗ 100

where test latency was the tail-withdrawal latency from either 50°C or 54°C water obtained after
drug administration, and baseline latency was the latency from either 50°C or 54°C water
obtained before drug administration. Maximum antinociceptive effects were also determined for
each drug or mixture at the group mean and individual level for each thermal stimulus intensity.
Maximum effect was defined as the highest effect produced by any dose. Group mean maximum
effects were compared using a one-way repeated-measures analysis of variance, and a Tukey
post-hoc test was conducted following a significant main effect. In addition, maximum effect
values were used in the analysis described in the next paragraph.
Theoretically, fentanyl/naltrexone mixtures should be useful to generate precise
increments in efficacy that can be used 1) to generate mixtures with efficacies not available in
existing single molecules, 2) to calibrate efficacy requirements for drug effects in different
procedures, and 3) to infer efficacies of other drugs tested in those procedures. For example, if
the relative efficacies of naltrexone and fentanyl are set arbitrarily at 0 and 1, respectively, then
mixtures of 1:3, 1:1 and 3:1 fentanyl/naltrexone (after correcting for ligand affinity) will have
relative efficacies along this continuum of 0.25, 0.5, and 0.75 respectively (i.e. relative efficacy =
fractional contribution of fentanyl to the total drug in the mixture). The efficacy requirement of a
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given procedure can then quantified by (a) testing effects of fentanyl and naltrexone alone and of
all three mixtures, (b) generating efficacy-effect functions to relate maximum effects of each
drug and mixture to the fentanyl proportion and associated relative efficacy, and (c) using
nonlinear regression to determine the EP50 value, defined as the “effective proportion” of
fentanyl to produce a maximum effect equal to 50% MPE in that procedure. EP50 values can then
be compared across procedures. Additionally, once the efficacy-effect relationships are
established, efficacy of a test drug can then be estimated as the fentanyl proportion that produces
maximum effects equivalent to that of the test drug. To evaluate the utility of this approach,
efficacy-effect curves were generated using nonlinear regression (GraphPad Prism, La Jolla, CA)
to fit maximum effects data for fentanyl alone, naltrexone alone, and each mixture at each
temperature using the equation:
𝐸𝑓𝑓𝑒𝑐𝑡
= 100
×

(𝑓𝑒𝑛𝑡𝑎𝑛𝑦𝑙 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛!"## !"#$% )

!"## !"#$%

𝐸𝑃50

+ (𝑓𝑒𝑛𝑡𝑎𝑛𝑦𝑙 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛!"## !"#$% ))

where fentanyl proportion was the fractional contribution of fentanyl to the total drug in the
mixture, and EP50 was the fentanyl proportion that produced a maximum effect equivalent to
50% maximum possible effect. Relative efficacies of test compounds were then estimated for
each individual monkey by comparing maximum effects of each drug at each temperature with
the group mean efficacy-effect curves. Specifically, relative efficacy was defined as the fentanyl
proportion at which maximum effects of the test drug deviated least from the efficacy-effect
functions. Deviation was quantified as the sum of the differences between test drug maximum
effect and efficacy-effect curve at both 50 and 54°C, and the fentanyl proportion was identified
at which deviation was smallest. Individual test drug values were then averaged to yield group
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mean values and these data were analyzed using a one-way repeated measures analysis of
variance. In the presence of a significant main effect, comparisons between test drug maximum
effects were made using the Tukey’s test.
For pretreatment and time course studies, two-way repeated-measures analysis of
variance was performed with experimental manipulation (e.g. pretreatment) and fentanyl dose or
time after fentanyl administration as the main independent variables. Following a significant
interaction, a Holm-Sidak post-hoc test was performed, and the criterion for significance was
p<0.05. Naltrexone pA2 values were determined as described previously (Bowen et al., 2002).

Drugs
Fentanyl HCl, (−)-naltrexone HCl, morphine sulfate, and (−)-oxycodone HCl were
supplied by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD). (−)Nalbuphine HCl was provided by Dr. Kenner Rice (Drug Design and Synthesis Section, National
Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda,
MD). (±)-Methadone HCl and (±)-buprenorphine HCl were purchased from Spectrum Chemicals
(Gardena, CA). NAQ HCl was synthesized and provided by Dr. Yan Zhang (Li et al., 2009).
Fentanyl, naltrexone, buprenorphine, nalbuphine, oxycodone, morphine, methadone, and all
mixtures were dissolved in sterile water. NAQ was dissolved in 50% dimethyl sulfoxide (SigmaAldrich, St. Louis, MO) and 50% sterile water. All drug doses were expressed as the salt forms
listed above, and administered intramuscularly in the thigh.

RESULTS
Fentanyl-Naltrexone fixed-proportion mixtures
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Across all baseline sessions before drug administration, monkeys always left their tail in
38°C water for 20 s, and the mean tail withdrawal latencies at 50°C and 54°C were 1.1 ± 0.5 s
and 0.7 ± 0.1 s, respectively. Figure 2 left panels show the antinociceptive effects of fentanyl
alone and following fixed naltrexone dose (0.0032-0.032 mg/kg, IM) pretreatments at 50°C (top)
and 54°C (bottom). Fentanyl alone produced dose-dependent and full (≥90%MPE)
antinociception at both temperatures in all monkeys. Increasing naltrexone dose pretreatments
produced parallel rightward shifts in the fentanyl dose-effect function at both temperatures.
Mean fentanyl ED50 values are shown in Table 3, and the naltrexone pA2 values (95%
confidence limits) were 8.58 (8.35, 8.82) and 8.50 (7.96, 8.52) for 50°C and 54°C, respectively.
Figure 2 right panels show the antinociceptive effects of fentanyl alone, naltrexone alone, and the
three fentanyl/naltrexone mixtures at 50°C (top) and 54°C (bottom). Maximum effect values
from mean dose-effect curves are shown in Table 1, and maximum effect values in individual
monkeys are shown in Table 2. As in the left panels, fentanyl alone produced dose-dependent
antinociception, whereas naltrexone alone was ineffective at both temperatures (<5% MPE).
Fentanyl/naltrexone mixtures produced a naltrexone proportion-dependent decrease in maximum
effects. Fentanyl alone and the 1:0.025 fentanyl/naltrexone mixture produced maximum effects
that were significantly different from both naltrexone alone and the 1:0.22 fentanyl/naltrexone
mixture at both 50°C and 54°C (50°C: F1.5,4.4=16.0, p=0.0111; 54°C: F1.9,5.7=31.3, p=0.0009).

MOR ligands
Figure 3 shows the antinociceptive effects of the MOR ligands NAQ, nalbuphine,
buprenorphine, oxycodone, morphine, and methadone at both 50°C (top) and 54°C (bottom).
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Maximum effects values from mean dose-effect curves are shown in Table 1, and maximum
effect values in individual monkeys are shown in Table 2. All drugs except NAQ produced
maximum or near maximum antinociceptive effects at 50°C, and the rank of order of maximum
effects at 54°C (from lowest to highest) was NAQ, buprenorphine, nalbuphine, morphine,
oxycodone and methadone. In general, the sensitivity of individual monkeys to declining
efficacy of fentanyl/naltrexone mixtures paralleled sensitivity to declining efficacy of test
compounds. For example, the 1:0.22 fentanyl/naltrexone mixture produced the greatest
antinociceptive effect at 54°C (44.2%MPE) in M1478, and this monkey also displayed the
greatest or close to the greatest maximum individual antinociceptive effect at 54°C following
nalbuphine, buprenorphine, or NAQ administration. In contrast, the 1:0.074 fentanyl/naltrexone
mixture produced the least antinociceptive effect at 54°C in M1503, and this monkey also
showed the weakest or close to the weakest individual antinociceptive effects at 54°C following
nalbuphine, buprenorphine, or NAQ administration.

Efficacy estimates of MOR ligands relative to fentanyl and naltrexone
Figure 4A shows efficacy-effect curves that relate %MPEmax effects of fentanyl,
naltrexone, and each mixture at 50 and 54°C to the proportion of fentanyl in the mixture from 0
(naltrexone alone) to 1 (fentanyl alone). Comparison of the nonlinear fits for the two different
temperatures using the extra sum-of-squares F-test demonstrated that each temperature data set
was best fit by different nonlinear functions (F2,6=7.3, p=0.0249). For 50°C, the hill slope was
4.26, EP50 value (95% confidence limits) was 0.39 (0.34, 0.46), and R2 was 0.99. For 54°C, the
hill slope was 6.66, EP50 value was 0.53 (0.41, 0.61), and R2 was 0.98. The 95% confidence
limits for the EP50 values at 50 and 54°C overlapped. Figure 4B shows the best fit for the
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maximum effect of each test drug to the efficacy-effect curves defined by the naltrexone-tofentanyl continuum. Using this analysis, the efficacy of each compound relative to the
naltrexone-to-fentanyl continuum was determined and results reported in Table 4. Comparison of
maximum effects demonstrated that fentanyl and methadone both produced significantly higher
maximum effects compared to buprenorphine, NAQ, and naltrexone (F2.3, 6.8=23.3, p=0.0008). In
addition, buprenorphine also produced significantly higher maximum effects compared to NAQ.

Effects of NAQ or fentanyl/naltrexone (1:0.22) pretreatment
Figure 5 shows cumulative fentanyl dose-effect functions alone or following a 15-min
pretreatment with the low-efficacy MOR ligand NAQ (10 mg/kg; left panels) or the low-efficacy
1:0.22 fentanyl/naltrexone mixture (0.032 mg/kg; right panels) at both 50°C (top) and 54°C
(bottom) thermal intensities, and fentanyl ED50 values are shown in Table 3. Consistent with the
results described in Figure 2, fentanyl alone produced dose-dependent antinociception at both
thermal intensities. NAQ pretreatment produced a significant (~9-fold) increase in the fentanyl
ED50 value at 54°C (Table 3) and significantly attenuated the antinociceptive effects of
cumulative 0.032 mg/kg fentanyl (fentanyl dose: F2,6=566.3, p<0.0001; NAQ: F1,3=176,
p=0.0009; interaction: F2,6=367.1, p<0.0001). Conversely, pretreatment with 0.032 mg/kg 1:0.22
fentanyl/naltrexone did not significantly increase in the fentanyl ED50 value at 54°C (Table 3),
although it did significantly decrease the antinociceptive effects of cumulative 0.032 mg/kg
fentanyl at 54°C (fentanyl dose: F2,6=24.4, p=0.0013; interaction: F2,6=16.1, p=0.0038).

Time course as a factor in drug-interaction studies
Figure 6 shows the time course of antinociception produced at 50 and 54°C by 0.056
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mg/kg fentanyl administered in combination with 0.0041 mg/kg naltrexone. When these two
doses were administered simultaneously (i.e. 0.056 mg/kg of the 1:0.074 fentanyl/naltrexone
mixture), submaximal antinociceptive effects were observed at both 50 and 54°C, and these
effects dissipated after 30-100 min. The effects of this bolus mixture after 10 min were similar
to the effects observed when the same dose of this mixture was tested as part of the cumulative
dose-effect curve (from Figure 2). Additionally, the effects of this bolus mixture dose were
similar to effects observed with the fentanyl dose was administered three min after the naltrexone
dose. However, when fentanyl was administered three min before naltrexone, the experiment had
to be terminated because of severe sedation and respiratory depression in two monkeys that
required additional naltrexone administration.

Discussion
The primary aim of the present study was to evaluate the degree to which fixedproportion mixtures of fentanyl and naltrexone would produce effects predicted by receptor
theory for mixtures of a competitive reversible agonist and antagonist targeting a common
receptor. A secondary aim was to evaluate the utility of results with fentanyl/naltrexone mixtures
for establishing an efficacy-effect scale that could be used to quantify (a) efficacy requirements
for different drug effects, and (b) relative efficacies of different MOR ligands. There were three
main findings. First, as predicted by receptor theory, the addition of naltrexone to fentanyl
produced a naltrexone proportion-dependent decrease in the maximal antinociceptive effects of
fentanyl/naltrexone mixtures. Second, the proportion of fentanyl in the mixtures served as a
metric for efficacy of the mixtures, and this scale provided a strategy for quantifying efficacy
requirements for different drug effects (i.e. antinociception at 50°C vs. 54°C) and relative in vivo
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efficacies of different MOR ligands. Lastly, the results reported here also provide insight into
factors that can limit utility of this approach. Overall, these results support the potential use of
agonist/antgonist mixtures as tools in basic research, while also suggesting factors that may
influence the usefulness of this approach.
Fentanyl alone produced dose- and thermal intensity-dependent antinociception in rhesus
monkeys, whereas naltrexone alone produced <10%MPE up to the largest doses tested. These
results were consistent with a large body of literature demonstrating the antinociceptive effects
of fentanyl in humans (Finch and DeKornfeld, 1967), nonhuman primates (Nussmeier et al.,
1991; Gatch et al., 1995; Maguire and France, 2014) and rodents (Millan, 1989; Walker et al.,
1994; Minami et al., 2009). Because naltrexone failed to produce significant antinociception, one
method to determine whether a behaviorally active dose range was administered would be to
give naltrexone as a pretreatment to cumulative fentanyl. In this experiment, receptor theory
would predict that increasing naltrexone fixed-dose pretreatments would produce parallel
rightward shifts in the fentanyl dose-effect function. The present results were consistent with this
hypothesis, and the naltrexone pA2 values reported in this study were consistent with previous
naltrexone studies in monkeys (Rowlett et al., 2000; Bowen et al., 2002; Gerak and France,
2007). Overall, these results provide an empirical foundation to interpret the antinociceptive
effects of fixed-proportion fentanyl and naltrexone mixtures.
Receptor theory predicts that fixed-proportion mixtures of a competitive reversible
agonist and antagonist should produce maximal effects that decline as the proportion of agonist
in the mixture declines. Results support this prediction. Specifically, the MOR agonist fentanyl
produced dose-dependent antinociception at both 50 and 54°C, and mixtures of fentanyl with the
MOR antagonist naltrexone produced decreasing maximal antinociceptive effects as the
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proportion of fentanyl in the mixture decreased. The declining maximal effects of
fentanyl/naltrexone mixtures with declining fentanyl proportions resembles the declining
maximal effects of mu agonists produced by pretreatments with irreversible antagonists (Zernig
et al., 1994; Walker and Young, 2002). As such, fixed-proportion mixtures with competitive
antagonists may serve as an alternative to use of irreversible antagonists for research on the role
of efficacy as a determinant of drug effects. This approach may be especially useful in research
on systems for which competitive antagonists are available, but irreversible antagonists are
not.
Because the agonist/antagonist proportion determined the apparent efficacy of a mixture,
this proportion could be used as a quantitative measure of in vivo efficacy. In the present study,
this metric was applied in two ways. First, we evaluated the efficacy requirements for
antinociception at 50 and 54°C by comparing the fentanyl proportion required to produce a
maximal effect of 50% MPE at each temperature. Although the 95% confidence limits for these
values overlapped, the higher mean value at 54°C agrees with other data to suggest that efficacy
requirements for antinociception are higher at 54°C than 50°C (Walker et al., 1993; Banks et al.,
2010b; Maguire and France, 2014). Additionally, although this study compared efficacy
requirements of similar endpoints (i.e. antinociception at two different stimulus intensities in
rhesus monkeys), it is theoretically possible to apply this approach across multiple endpoints that
could include not only other behavioral and physiological endpoints in rhesus monkeys, but also
endpoints in other species or in in vitro assays. For example, two undesirable effects of MOR
agonists that limit their clinical utility are respiratory depression and abuse liability, and
fentanyl/naltrexone mixtures could be used to quantify the efficacy requirement for each of these
or any other MOR agonist effect of interest. These experiments would also provide empirical
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data on the utility of agonist/antagonist mixtures to assess the efficacy requirements of different
experimental endpoints.
A second implication of the present study was that fentanyl/naltrexone mixtures could be
used to stratify MOR ligands based on their in vivo antinociceptive efficacy in rhesus monkeys.
In the present study, NAQ produced < 10%MPE and these results are consistent with and extend
previous findings in mice (Zhang et al., 2014; Yuan et al., 2015) and rats (Siemian et al., 2016).
Buprenorphine (Walker et al., 1995; Maguire and France, 2014), nalbuphine (Walker et al.,
1993; France and Gerak, 1994; Banks et al., 2010b), morphine (Bowen et al., 2002), oxycodone,
and methadone (Stevenson et al., 2003; Banks et al., 2010b) produced dose- and thermal
intensity-dependent antinociception in the present study, and these results were generally
consistent with the extant literature examining MOR agonists in a warm-water tail-withdrawal
procedure in monkeys. With one major exception (see below regarding nalbuphine), the order of
MOR efficacies for these drugs as ranked here agrees with the order of efficacies as determined
by in vitro approaches such as agonist-stimulated GTPγS binding (Selley et al., 1998; Alt et al.,
2001; Yuan et al., 2015). Specifically, both approaches yield a rank order of lowest-to-highest
efficacy of naltrexone < NAQ < buprenorphine < morphine < oxycodone < fentanyl <
methadone. By comparing effects of these mu agonists to effects of fentanyl/naltrexone mixtures,
it was possible not only to rank order drug efficacies, but also to provide a quantitative measure
of those relative efficacies, expressed as fentanyl proportion.
Results with nalbuphine in the present study did not agree with previous in vitro results
using agonist-stimulated GTPγS binding with either mouse MOR (Selley et al., 1998) or rat
MOR (Alt et al., 2001). The basis for this difference between published GTPγS results and
antinociceptive efficacy in rhesus monkeys remains to be empirically determined. Although there
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are no published GTPγS results with any MOR ligand using monkey MOR, two lines of
evidence support the conclusion that nalbuphine functions as a higher efficacy MOR ligand than
buprenorphine in rhesus monkeys. First, in HEK cells expressing MOR and examining inhibition
of forskolin-stimulated cAMP accumulation, nalbuphine produced similar efficacy to morphine
(Gharagozlou et al., 2003). Second, the present nalbuphine results demonstrating greater
antinociceptive effects of nalbuphine compared to buprenorphine are generally consistent with
previously published studies in nonhuman primates (Walker et al., 1993; Walker et al., 1995;
Maguire and France, 2014). In addition to these antinociceptive studies, nalbuphine also shows
higher efficacy than buprenorphine in an assay of schedule-controlled responding. For example,
nalbuphine produced dose-dependent and near complete suppression of operant responding
(Stevenson et al., 2003; Banks et al., 2010b), whereas buprenorphine decreased operant
responding to approximately 65% of control (Negus et al., 2002). Overall, the present results
highlight potential species differences in MOR ligand efficacy and support the utility of
nonhuman primates in preclinical pharmacology research.
Although the present results support the concept that agonist/antagonist mixtures can be
used manipulate apparent in vivo efficacy, these results also revealed factors that can influence
the precision of this approach. Two particular limitations will be mentioned here. First, the
efficacies of the constituent drugs in a mixture define the upper and lower boundaries of efficacy
that can be assessed. For example, in the present study, fentanyl served as the agonist, and
studies of in vitro agonist-stimulated GTPγS binding suggest that some MOR ligands (e.g.
methadone) may have higher efficacy than fentanyl (Selley et al., 1998; Alt et al.,
2001). Because fentanyl defines the upper boundary of efficacy than can be achieved with
fentanyl/naltrexone mixtures, these mixtures would not be useful for scaling effects of drugs like
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methadone that may have higher efficacy than fentanyl. Similarly, these mixtures would not be
useful for scaling effects of drugs that have lower efficacy than naltrexone.
Second, although agonist/antagonist proportions can be precisely controlled in a
mixture, the pharmacokinetics and associated time courses of the constituent drugs play a key
role in determining the proportional drug concentrations at receptor targets after a in vivo drug
administration. For example, in the present study, cumulative administration of the 1:0.074
fentanyl/naltrexone mixture could be safely studied at doses up to 0.32 mg/kg. However, bolus
administration of this mixture at dose of 0.1 mg/kg fentanyl + 0.0074 mg/kg naltrexone could not
be studied due to the onset of severe sedation and respiratory depression in at least one
monkey. This suggests that, after bolus administration, fentanyl distributes more quickly than
naltrexone to receptors that mediate sedation and respiratory depression. This difference may be
mitigated during cumulative dosing by sustained effects of naltrexone doses administered early
in the dosing regimen. Additionally, the impact of these pharmacokinetic issues may be
influenced by both the agonist/antagonist proportion and overall mixture dose. For example, in
the present study, both cumulative and bolus administration of 0.056 mg/kg 1:0.074
fentanyl/naltrexone produced similar effects. However, administration of fentanyl just three min
before naltrexone resulted in severe sedation and respiratory depression. Overall, these results
highlight time course of drug effects as a key consideration in the deployment of competitive
agonist/antagonist mixtures for both basic research or clinical studies.
As a final note, the present results with fentanyl/naltrexone mixtures can be compared to
development of opioid formulations that include a MOR agonist in combination with the
competitive reversible antagonist naloxone (e.g. fixed-proportion formulations of oxycodone +
naloxone or buprenorphine + naloxone) (Mendelson and Jones, 2003; Chen et al., 2014; Fanelli
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and Fanelli, 2015; O'Brien, 2015). Consumption of these products by intended enteral routes of
administration results in naloxone distribution to the gastrointenstinal tract (which may reduce
constipating effects of the agonist), but limited distribution to the central nervous system due to
extensive first-pass metabolism by the liver (resulting in limited interference with centrally
mediated agonist effects). However, parenteral administration bypasses first-pass metabolism,
resulting in greater naloxone distribution to the central nervous system and potential blockade of
centrally mediated agonist effects and/or precipitation of withdrawal in opioid-dependent
subjects. As a result of these characteristics, naloxone combination products are thought to have
fewer gastrointestinal side effects and lower abuse liability than the agonists alone. The
experimental design deployed in the present study could be used to test this hypothesis, with the
caveat that naloxone’s relatively short duration of action may hamper naloxone’s utility for this
type of research. For example, naloxone should be more potent to produce proportion-dependent
downward shifts in agonist dose-effect curves for gastrointenstinal than centrally-mediated
effects after enteral but not parenteral administration. The present study also suggests how the
general concept of agonist+antagonist mixtures can be expanded beyond naloxone-containing
combination products to include other antagonists such as naltrexone, or agonist+antagonist
mixtures targeting other receptors, yielding mixtures with other pharmacological profiles.
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Figure Legends
Figure 1: Theoretical curves simulated from the Furchgott equation for receptor theory (Ruffolo, 1982).
Left panel shows rightward shifts in a competitive reversible agonist dose-effect function after pretreatment
with increasing fixed doses of a competitive reversible antagonist. Right panel shows downward shifts in a
competitive reversible agonist dose-effect function when agonist and antagonist are co-administered in
fixed-proportion mixtures. Equations and definition of terms are shown below the panels. For this
simulation, agonist dose A and antagonist dose B vary in KD units (i.e. at a dose of 1, dose = KD); Rt was set
arbitrarily at 100, and all other variables were set arbitrarily at 1. Note that in the left panel, antagonist dose
is a fixed dose B that remains constant across a range of agonist doses. For the right panel, antagonist dose
is a fixed proportion p of the agonist dose A, such that B=pA and increases in agonist dose are accompanied
by increases in antagonist dose.

Figure 2: Effects of fixed-dose naltrexone pretreatments to fentanyl and fixed-proportion
fentanyl/naltrexone mixtures in an assay of thermal nociception in male rhesus monkeys. Left panels show
effects of fentanyl alone and after increasing naltrexone doses administered as a 15-min pretreatment to
fentanyl at 50°C (top) and 54°C (bottom) thermal intensities. Right panels show effects of fentanyl alone,
naltrexone alone, and three fentanyl/naltrexone mixtures at 50°C (top) and 54°C (bottom). Abscissae:
cumulative intramuscular fentanyl dose (left panels) or cumulative drug dose (right panels) in mg/kg. Note
that for data with fentanyl/naltrexone mixtures in the right panels, the abscissa shows the fentanyl dose in
the mixture, and the naltrexone dose = fentanyl dose x naltrexone proportion. Ordinates: % maximum
possible effect (%MPE). All points represent mean ± SEM of 4 monkeys.

Figure 3: Effects of six different MOR ligands in an assay of thermal nociception in male rhesus monkeys.
Top panel shows effects of NAQ, nalbuphine, buprenorphine, morphine oxycodone, and methadone at
50°C, and bottom panel shows effects at 54°C. Abscissae: cumulative intramuscular drug dose (mg/kg).
Ordinates: % maximum possible effect (%MPE). All points represent mean ± SEM of 4 monkeys.
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Figure 4: Top panel (A) shows maximum antinociceptive effect at 50°C (triangles) and 54°C (squares) as a
function of the fentanyl proportion in the fentanyl/naltrexone mixture in male rhesus monkeys. Bottom
panel (B) shows empirically determined maximum antinociceptive effects of NAQ, buprenorphine,
nalbuphine, morphine, oxycodone, and methadone. Results were fit to the model generated from the top
panel, and relative efficacy of each ligand was estimated as the fentanyl proportion to produce maximum
effects at 50 and 54°C most like the test ligand. Abscissae: Efficacy expressed as Proportion Fentanyl. “0”
denotes naltrexone alone, “1” denotes fentanyl alone, and the efficacy of each mixture (Emix) was
calculated as the fractional contribution of fentanyl to the mixture as described in Methods. Ordinates:
Maximum Effect. All points represent mean ± SEM of 4 monkeys.

Figure 5: Effects of cumulative fentanyl (0.001-0.32 mg/kg, IM) administered either alone or following a
15-min pretreatment with either 10 mg/kg NAQ (left panels) or 0.032 mg/kg fentanyl/naltrexone (1:0.22)
(right panels) in rhesus monkeys. Abscissae: cumulative intramuscular fentanyl dose (mg/kg). Ordinates: %
maximum possible effect (%MPE). All points represent mean ± SEM of 4 monkeys. Filled points denote
statistical significance (p<0.05) compared to fentanyl alone.

Figure 6: Time course of antinociceptive effects of 0.056 mg/kg fentanyl in combination with 0.0041
mg/kg naltrexone administered simultaneously as a bolus dose of the 1:0.074 fentanyl/naltrexone mixture or
with the naltrexone dose administered as a 3-min pretreatment to the fentanyl dose in rhesus monkeys.
Antinociceptive effects of cumulative 0.056 mg/kg 1:0.074 fentanyl/naltrexone from Figure 2 are also
plotted for comparison. Abscissae: fentanyl dose (mg/kg). Ordinate: % maximal possible effect (%MPE).
Each point represents mean ± SEM of 4 monkeys.

115

Table 1: Group mean %MPEmax values and (±SEM) for each fentanyl/naltrexone combination or
test drug administered in an assay of thermal nociception at 50°C and 54°C in rhesus monkeys
(n=4).
%MPEmax
(SEM)

Drug or Drug Mixture
50°C
Fentanyl

100 (0)

54°C
∗

,†

96.4 (2.8)
∗

1:0.025
Fentanyl/Naltrexone
1:0.074
Fentanyl/Naltrexone
1:0.22
Fentanyl/Naltrexone
(−)-Naltrexone

∗

100 (0)

∗

,†

95.3 (4.7)
∗

70.8
(24.2)
14.5 (9.5)

,†

,†

-1.8 (5.6)

40.4
(14.9)
12.9
(10.7)
0.9 (0.4)

(±)-Methadone

100 (0)

100 (0)

(−)-Oxycodone

100 (0)

89.5 (6.7)

(−)-Morphine

100 (0)

78.1 (9.9)

(−)-Nalbuphine

100 (0)

(±)-Buprenorphine

93.3 (6.7)

64.1
(14.5)
14.0 (6.0)

NAQ

8.9 (6.9)

5.1 (3.7)

Significantly different from Naltrexone (p < 0.05)

† Significantly different from 1:0.025 Fentanyl/Naltrexone mixture (p < 0.05)

Table 2: Individual %MPEmax values for each fentanyl/naltrexone combination or test drug
administered in an assay of thermal nociception at 50°C and 54°C in rhesus monkeys.
%MPE
max

50°
C
M1414 M1473 M1478 M150
3
100
100
100
100

54°
C
M1414 M1473 M1478 M1503
87

100

100

100

1:0.025
Fentanyl/Naltrexone
1:0.074
Fentanyl/Naltrexone
1:0.22
Fentanyl/Naltrexone

100

100

100

100

81.1

100

100

100

84.2

100

100

3.3

37.6

62.7

62.2

4.7

9

6.6

42.2

10.4

18.1

10

44.2

1.1

(−)-Naltrexone

9.5

2.1

-12.6

-1.6

3.2

1.8

-0.3

0.6

(±)-Methadone

100

100

100

100

100

100

100

100

(−)-Oxycodone

100

100

100

100

71.4

100

86.1

100

(−)-Morphine

100

100

100

100

74.9

52.8

54.7

100

(−)-Nalbuphine

100

100

100

100

52.8

100

71.9

31.7

(±)-Buprenorphine

73.2

100

100

100

32.1

18.7

29.3

16.5

NAQ

4.6

5.9

28.8

8

6.4

1.1

16.1

2.8

Drug or Drug
Mixture
Fentanyl

Table 3: Fentanyl ED50 values and (95% confidence limits) administered alone or following
a 15-min pretreatment with naltrexone (0.0032-0.032 mg/kg), 10 mg/kg NAQ, or 0.032
mg/kg fentanyl/naltrexone (1:0.22) mixture in an assay of thermal nociception at 50°C and
54°C. Data are presented as the mean of 3 monkeys for the naltrexone pretreatment studies
and mean of 4 monkeys for the NAQ and fentanyl/naltrexone mixture pretreatment studies. ‡
denotes non-overlapping 95% confidence limits (CL).
ED50 in mg/kg (95% CL)
50°C
Fentanyl alone
+ 0.0032 mg/kg Naltrexone
+ 0.01 mg/kg Naltrexone
+ 0.032 mg/kg Naltrexone
Fentanyl alone
+ 10 mg/kg NAQ pretreatment
Fentanyl alone
+ 0.032 mg/kg
Fentanyl/Naltrexone
(1:0.22) pretreatment

0.006 (0.006,
0.006)
0.021 (0.016,
0.028) ‡
0.018 (0.013, 0.05)
‡

54°
C
0.018 (0.018, 0.018)
0.035 (0.018, 0.069)
0.169 (0.057, 0.228) ‡

0.057 (0.043,
0.128) ‡
0.006 (0.005,
0.006)
0.041 (0.014,
0.118) ‡
0.006 (0.005,
0.006)

0.257 (0.109, 0.608) ‡

< 0.017 (0.002,
0.18) §

0.035 (0.015, 0.08)

0.014 (0.012, 0.017)
0.155 (0.122, 0.197) ‡
0.014 (0.012, 0.017)

§ ED50 value could only be determined in 2 out of 4 monkeys because no fentanyl dose
produced < 50%MPE.

Table 4: Estimated efficacy of each compound relative to the naltrexone-to-fentanyl
continuum in proportion fentanyl units (95% confidence limits) for each of the eight
MOR ligands tested in rhesus monkeys (n=4). Individual %MPEmax values were fitted
to the nonlinear function generated from the group mean results shown in Figure 4A.
Test Drug

Fentanyl

Proportion Fentanyl (95%
CL)
0.94 (0.77, 1.12) ¶, #, ∏

(±)-Methadone

1 (1, 1) ¶, #, ∏

(−)-Oxycodone

0.86 (0.58, 1.13)

(−)-Morphine

0.71 (0.4, 1.02)

(−)-Nalbuphine

0.7 (0.37, 1.03)

(±)-Buprenorphine

0.51 (0.47, 0.54) #

NAQ

0.26 (0.16, 0.36)

(−)-Naltrexone

0.12 (-0.1, 0.33)

¶ Significantly different from Naltrexone (p < 0.05)
# Significantly different from NAQ (p < 0.05)
∏ Significantly different from Buprenorphine (p < 0.05)
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Chapter 5: Discussion

This dissertation examined MOR agonist interactions on preclinical endpoints related to
pain in nonhuman primates. There were three main findings. First, NMDA receptor antagonists
failed to enhance the antiallodynic effects of either a moderate (nalbuphine) or high (oxycodone)
efficacy MOR agonist. Second, the NOP receptor agonist Ro 64-6198 potentiated the
antinociceptive effects of MOR agonists regardless of efficacy; however, the effect was far more
modest than previously reported and was only observed under a narrow range of experimental
conditions. Third, fixed-proportion MOR antagonist (i.e. naltrexone) and agonist (i.e. fentanyl)
mixtures were successful in decreasing antinociceptive efficacy in an antagonist proportiondependent manner. Overall, the results described in this dissertation add to the growing body of
literature examining candidate opioid adjuncts to produce opioid-sparing effects by identifying
pharmacological and experimental limitations of previously examined opioid interactions and in
strengthening the case for employing complementary behavioral measures in opioid combination
experiments. Furthermore, this dissertation provided several experimental design insights to
guide future preclinical pain and candidate analgesic drug development research.

1. NMDA antagonist and opioid agonist interactions
The main finding of Chapter 2 was that the NMDA receptor antagonists ketamine and
MK-801 failed to enhance the antiallodynic effects of either the moderate (i.e. nalbuphine) or
high (i.e. oxycodone) efficacy MOR agonists. Furthermore, NMDA antagonist and MOR agonist
combinations reduced the experimental therapeutic index of the MOR agonists to selectively
produce antiallodynia vs. behavioral sedation as compared to the MOR agonists alone.
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Generally, the experimental therapeutic index decreased as the amount of NMDA receptor
antagonist in the mixture increased. This would suggest that increasing NMDA antagonist doses
in fixed proportion combinations with MOR agonists would be more detrimental than producing
clinically beneficial effects. These results further highlight (1) the utility of nonhuman primates
in preclinical assessments of candidate analgesics and (2) the necessity of employing
complementary assays to discern the selectivity of antinociceptive vs. sedative effects of putative
MOR agonist combination medication therapies for clinical pain management.
The reported antinociceptive interactions between the NMDA receptor antagonists and
MOR agonists were consistent with previous reports in rhesus monkeys (Banks et al, 2010) and
humans (Lee and Lee, 2016). However, these results are inconsistent with a previous study in
squirrel monkeys (Allen and Dykstra, 2001). The lack of a synergistic interaction in Chapter 2
results and those reported in Banks (2010) are in contrast to results reported by Allen and
Dykstra (2001). These differences are most likely attributed to the noxious stimulus utilized in
each experimental design. For example, a thermal noxious stimulus was utilized in both Chapter
2 and Banks (2010) whereas Allen and Dykstra (2001) utilized a mild electrical shock as the
noxious stimulus. Interactions between NMDA receptor antagonists and MOR agonists have
been previously shown to differentially affect antinociceptive responses depending upon
stimulus modality. For example, in clinical laboratory experiments the NMDA receptor
antagonist ketamine potentiated the antinociceptive effects of fentanyl against an electrical, but
not thermal noxious stimulus (Tucker et al, 2005). Thus, stimulus modality appears to be a
critical factor in the antinociceptive interactions between NMDA receptor antagonists and MOR
agonists. These discrepancies may suggest further limitation to any potential clinical utility that
NMDA antagonists and MOR agonists may have in the management of pain.
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The reported antinociceptive interactions between NMDA receptor antagonists and MOR
agonists in Chapter 2 were also inconsistent with several previous rodent studies examining
MOR agonist and NMDA antagonist interactions (Baker, Hoffman, Meert, 2002; Holtman Jr et
al, 2008). For example, dextromethorphan, ketamine, and ketamine metabolites (S(+)- and R(-)norketamine) were previously shown to enhance the antinociceptive effects of MOR, but not
KOR and DOR, agonists in rats across multiple pain states (Baker, Hoffman, Meert, 2002;
Holtman Jr et al, 2008). Since the noxious stimuli didn’t differ between Chapter 2 and the
aforementioned rodent studies (e.g. warm-water tail withdrawal vs. hot plate, respectively), this
apparent discrepancy suggests differences between rodents and nonhuman primates in
antinociceptive effects mediated by NMDA receptor activity (i.e. neuroanatomical differences).
Moreover, one of the major differences between the rodent studies and the experiments in Aim 1
is several of the NMDA receptor antagonists utilized (eg. dextromethorphan, S(+)- and (R-)norketamine). A meta-analysis suggested that ketamine combinations with opioids for
management of acute pain were not superior to the opioid alone and may exacerbate some
undesirable side effects (Lee and Lee, 2016). Thus, the clinical utility of ketamine or other
NMDA antagonists as an adjunct to MOR agonists for the management of pain is very unlikely.
Moreover, ketamine-MOR combinations in several clinical trials lead to increased
“neuropsychiatric” side effects in some patients (Lee and Lee, 2016). Overall, the results
reported in this dissertation were consistent with conclusions from this meta-analysis and support
the utilization of nonhuman primates and multi-modal preclinical dependent measures to develop
candidate analgesics.

2. NOP agonist and opioid agonist interactions
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The main finding of Chapter 3 was that the high efficacy NOP receptor agonist Ro 646198 (Jenck et al, 2000) potentiated the antinociceptive effects of MOR agonists regardless of
efficacy; however, this effect was far more modest than previous reports, and was only observed
to occur under a narrow range of experimental conditions. Furthermore, the previously reported
antinociceptive effects of Ro 64-6198 alone in rhesus monkeys (Ko et al, 2009; Podlesnik et al,
2011; Cremeans et al, 2012) were not replicated at comparable or 3-fold higher doses (0.1 and
0.32 mg/kg IM, respectively).
The results indicating that NOP agonists did not impact our complementary undesirable
MOR agonist effect add to the existing reports of buprenorphine and NOP agonist combinations
and bivalent MOR-NOP agonists. Ro 64-6198 had been previously shown not to increase the
potency or efficacy for buprenorphine to produce respiratory depression or pruritis (Cremeans et
al, 2012). Furthermore, the mixed-action MOR-NOP agonist BU08028 showed no significant
production of respiratory depression (compared to MOR agonist alone), and did not maintain
drug-self-administration (Cremeans et al, 2012; Ding et al, 2016). While some of these
undesirable effects may still persist at higher doses of buprenorphine+Ro 64-6198 combinations
(i.e. abuse liability and respiratory depression), the increase in antinociceptive potency compared
to buprenorphine alone may result in a decrease in the occurrence of these opioid-related adverse
effects (Li, 2019). Overall, these data would support the utility of MOR+NOP combinations for
clinical pain treatment.
One potential limitation of the clinical utility of NOP+MOR combinations is the lack of
pharmacological selectivity as NOP activity may potentiate the undesirable effects of MOR
agonists as well. The potentiation of both the antinociceptive effects and antagonism of ratedecreasing effects of nalfurafine by Ro 64-6198 at a single dose (0.01 and 0.001 mg/kg,
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respectively) further complicate the translatability of NOP+MOR agonist combinations to
clinical utility. These findings suggest that Ro 64-6198 potentiation is perhaps not selective for
(1) mu-opioid receptor agonists and (2) opioid receptor-mediated antinociception. If this
potentiation is not selective for MOR agonists, this could suggest another false-positive result as
DOR and KOR agonists will produce antinociception in preclinical assays, but are not clinically
useful analgesics. However, this could also suggest that mixed action MOR/KOR agonists (such
as butorphanol) may be viable candidates for future NOP combinations.

3. Opioid adjuncts as a useful approach to produce an opioid-sparing effect
In comparison with interactions between MOR agonists and other candidate adjuncts
targeting other receptors, the MOR agonist antinociceptive potentiation reported in this
dissertation is much more modest (NOP-MOR) or nonexistent (NMDA-MOR). For a list of
previous Mu-Plus interactions, see Table 1. For example, the serotonin uptake inhibitors
fluoxetine and clomipramine potentiated the antinociceptive effects of MOR agonists in rats and
rhesus monkeys, respectively, by nearly 10-fold (Nayebi et al, 2001; Banks et al, 2010).
Furthermore, the cannabinoid receptor agonists CP 55,940 and Δ9-THC both potentiated the
antinociceptive effects of MOR agonists nearly 10-fold in both rhesus monkeys and rats
(Maguire and France, 2014, 2018). Moreover, in some cases, DOR potentiation of MOR
mediated antinociception was greater than reported in Chapters 2 and 3 experiments (e.g. SNC80
+ methadone, fentanyl, or nalbuphine), but was roughly similar with other DOR-MOR
combinations (e.g. SNC80 + morphine and MSF61 + fentanyl) (Stevenson et al, 2003; Negus et
al, 2009). Additionally, the KOR agonist nalfurafine potentiated oxycodone antinociception in
rodents to a greater degree, roughly 10-fold, than results reported in the Aim 1 and 2 experiments
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(Townsend et al, 2017), and mixtures with the KOR agonist spiradoline and morphine or
etorphine potentiated antinociceptive effects of the MOR agonist alone by roughly 10-fold and 5fold, respectively (Minervini et al, 2018). Overall, the absence of NMDA antagonist
enhancement of MOR agonist antinociception and the small magnitude of NOP agonist
enhancement of MOR agonist antinociception compared to published literature with other
potential adjuncts targeting other receptor systems do not support the further development of
either NMDA antagonists as MOR agonist adjuncts but does support NOP agonists as candidate
analgesics for the treatment of acute pain. However, it is unknown if NOP-MOR agonist
combinations or bivalent ligands will be superior to MOR agonists alone in the production of
analgesia. Finally, the results do provide insight into the applicability of opioid-combination
experiments for considerations into the experimental designs of future MOR agonist combination
medication development experiments.
Despite promising results from previous proposed adjunct combinations (eg. serotonin
uptake inhibitors, cannabinoid receptor agonists, DOR agonists, KOR agonists, NOP agonists,
imidazoline I2 receptor agonists) there does not seem to be much translational progress from
preclinical results to clinical application of multiple molecule therapies. The increasing number
of recent clinical trials suggests there seems to be more interest in one alternative to fixedproportion drug mixtures: bivalent ligands that target multiple receptor systems of interest. For
example, the NOP-MOR bivalent ligand cebranopadol has been investigated in a wide range of
clinical trials to varying successes. However, each of these approaches has their pros and cons.
For example, combination medication therapies have the advantage of (typically) being readily
available, FDA-approved medications that healthcare professionals can prescribe to patients.
Moreover, this approach may allow for the “fine-tuning” of the proportions of each drug in the
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mixture towards an effort of maximizing desirable effects and minimizing undesirable effects.
However, fixed-proportion combination opioid medications require overlapping pharmacokinetic
characteristics of each drug, such as onset and duration of action. On the other hand, bivalent
ligands have the capacity to bypass the requirement for pharmacokinetic concordance, as a single
molecule will activate both receptors of interest. However, these bivalent compounds would
require a longer time to develop and move through the drug development stages to ensure safety
and efficacy compared to existing and approved medications. Moreover, this approach may only
be viable for certain receptor systems with similar enough binding pockets to allow an overlap in
the molecule’s pharmacophore composition such that the molecule could appreciably activate
both receptors. It seems likely that the best choices between these two approaches would be on a
case-by-case basis, but experiments directly comparing the two could greatly elucidate the
situations under which each approach would be the most beneficial

4. Fixed-proportion opioid agonist and antagonist interactions
The main finding of Chapter 4 was that fixed-proportion mixtures of a competitive
agonist and antagonist at a common receptor produced antagonist proportion-dependent
decreases in efficacy. These results showed the usefulness of agonist-antagonist fixed-proportion
combinations to predict a “window of effect” detectable by various assays. In this case, the
windows of effect of MOR agonists for warm water tail withdrawal at both 50 and 54 °C in
nonhuman primates was determined. This could allow for researchers to probe a wide variety of
different assays and compare the efficacy requirements for agonists active at various receptor
systems to produce an effect in a given assay. Recently, this approach has been shown to be
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reproducible with rats in both a tail-withdrawal and drug-discrimination procedure utilizing
MOR agonists (Schwienteck, 2019).
Efficacy is defined as a ligand’s ability to activate a receptor to generate a response in a
biological system and has long been known to be a major determinant in drug effects both in
vivo and in vitro (Blumenthal and Garrison, 2011). One of the major themes of this dissertation
was determining the role of MOR efficacy in production of behavioral effects (e.g.
antinociception and decreases in operant rates of responding) alone and in combination with
other compounds (i.e. NMDA antagonists, NOP agonists, and naltrexone). This work further
expanded upon the concept of efficacy requirements for the detection of a biological effect in in
vivo behavioral assays such that moderate efficacy MOR agonists (e.g. buprenorphine) are
incapable of producing (1) meaningful antinociception at higher intensity noxious stimuli (ie.
54°C) and (2) significant decreases in operant rates of responding, both of which high efficacy
agonists (e.g. fentanyl) are capable of producing.
These reported results support previous suggestions that efficacy requirements to produce
antinociception and other effects can be ranked, and the current data would propose the efficacyeffect ranking of these procedures as 50°C antinociception < schedule-controlled responding <
54°C antinociception (Walker et al, 1993; Banks et al, 2010; Maguire and France, 2014). These
findings suggest interesting implications for both preclinical research and clinical practice as
they propose the potential for behavioral assays to be ranked based upon their sensitivity for
detection of biological effects along a specific range of drug efficacies. If the receptor system has
been adequately probed, efficacy-effect procedures could be a useful tool to inform researchers
of the proper assay to employ when investigating a relatively novel compound to ensure
detection of any potential biological effects. One limiting factor, however, is that it is unknown if
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these results would be supported with drugs active at a system other than the MOR. One would
hypothesize that the results are translatable due to the generalizability of the properties of
“efficacy” across a range of drug classes. Clinically speaking, these efficacy-dependent effects
support the idea that low efficacy MOR agonists are effective in reduction of more moderate
pain states with a lower incidence of undesirable side effects (Davis, 2012), while higher efficacy
MOR agonists would be more effective in treatment of more severe pain states. Clinically, this
could provide a tool for physicians to tailor drug effects to the need of the patient. For example,
this approach could be used to combine fentanyl and naltrexone at a precise fixed-proportion to
mitigate a patient’s moderate pain symptoms without the potential for producing respiratory
depressant effects, such as with buprenorphine, but permitting a higher degree of antinociceptive
efficacy.

5. In vivo investigation of NAQ in rhesus monkeys
This work was the first evaluation of the in vivo efficacy of the novel MOR ligand, 17cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan
(NAQ) in monkeys. NAQ was shown to be ineffective in producing any suppression of operant
rates of responding in the assay of schedule-controlled responding and was shown to be
ineffective in producing antinociception in the tail withdrawal assay. These effects were
consistent up to doses which both (1) antagonized the antinociceptive effects of fentanyl in the
tail-withdrawal procedure, and (2) were maximally allowed due to solubility constraints. These
results were generally consistent with those in rats, but subtle species differences did emerge.
One study reported no significant decreases in rates of responding in a drug discrimination
procedure or significant antinociception in a tail-flick procedure (Schwienteck et al, 2019), and
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another reported no significant antiallodynia but a significant decrease in rates of foodmaintained responding (Siemian et al, 2016). The antagonistic effects of NAQ were also
generally consistent with previously reported effects in both mice and rats (Yuan et al, 2015;
Siemian et al, 2016; Schwienteck et al, 2019). Overall these results demonstrate a concordance in
NAQ activation of the MOR receptor at the organismal level from rodents to nonhuman primates
and further support the utility of NAQ as a low efficacy MOR ligand.
Although the modeling resulted in NAQ being quantified as 0.25 proportions of fentanyl,
this was still shown to be insufficient to detect any behavioral effect in either of our assays. This
suggests that in either schedule-controlled responding or warm-water tail withdrawal, that
ligands producing ≤ ~25% of fentanyl’s receptor activation will fail to produce a detectable
effect suggesting that these procedures are only useful in probing higher efficacy MOR
compounds (≥ ~50% of fentanyl receptor activation). In light of this the need to both (1) develop
new and (2) identify existing behavioral assays which will allow for the detection of effects
along the lower 50% of the fentanyl proportion efficacy range is an imperative goal. One such
potential assay to detect effects of lower efficacy MOR agonists could be intracranial selfstimulation. For example, NAQ has been shown to produce detectable behavioral effects
including rate-decreasing effects in this procedure in opioid-naïve rats and weak facilitation in
opioid-exposed rats (Altarifi et al, 2015; Moerke & Negus, 2019). Moreover, drug discrimination
procedures may also provide an avenue for detection of behavioral effects mediated by lower
efficacy MOR ligands as NAQ was reported to occasion fentanyl-appropriate responding in rats
trained to discriminate fentanyl (Schwienteck et al, 2019). Overall, the literature supports the
utility of NAQ as a low efficacy MOR ligand in preclinical pharmacological research.
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6. Experimental design considerations for future preclinical pain research
Tail-Withdrawal Procedure
The warm-water tail withdrawal procedure has been historically used in the field of
behavioral pharmacology to evaluate the antinociceptive effects of novel compounds, including
novel MOR agonists. However, the warm-water tail withdrawal procedure is not without
limitations and the predictive validity of non-opioid candidate analgesics in the warm-water tail
withdrawal procedure has not been great. One limitation is that the procedure relies entirely upon
a reflexive behavior that produces solely a transient nociceptive response that can be “escaped”
by removal of the tail from the noxious stimulus (e.g. heated thermos) (Negus, 2019). Because
the tail withdrawal behavior relies on a reflex arc within one area of the spinal cord (Weng and
Schouenborg, 1996), the receptors mediating any antinociceptive effect may be (1) fewer in
number than those responsible for more complex pain states and (2) limited to sub-cortical areas
which are crucial in the emotional aspect of pain perception (Negus, 2019). In support of this
hypothesis, activation of peripheral opioid receptors is sufficient to produce antiallodynia in tailwithdrawal procedures (Ko et al, 1998, 1999, 2002), however neither peripheral nor centrally
activating KOR ligands are currently clinically utilized analgesics. This result suggests a major
limitation in the tail-withdrawal procedure if our intention is to translate results to a clinical
situation.
The tail-withdrawal procedure does appear to model aspects of acute pain; for example,
some of the most robustly effective compounds to produce antinociception in this procedure are
MOR agonists and MOR agonists are still the most commonly utilized clinical interventions for
moderate to severe acute pain (e.g. post-operative pain states) (Whiteside et al, 2008). However,
the translatability of the tail withdrawal procedure to human pain states is highly problematic for
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three major reasons: (1) the high potential for false-positives, (2) the issue of dose-requirements
to detect some effects, and (3) the inability to detect effects for clinically utilized analgesics (e.g.
NSAIDs).
Because the tail withdrawal procedure is a pain-stimulated endpoint (meaning that the
measured response increases in duration, intensity, or frequency in the presence of the noxious
stimulus), it is highly susceptible to false-positives from compounds that produce motor
impairment (Negus, 2019). If a drug is capable of decreasing behavior, then the drug should
decrease the tail withdrawal response (indicative of antinociception in this procedure) at some
dose. This phenomenon is well characterized; for example, MK-801, PCP, THC, loperamide, and
nalfurafine have all been reported to produce decreases in tail withdrawal behaviors in this
procedure despite none of these compounds being clinically prescribed analgesics (France et al,
1989; Endoh et al, 2001; Butelman et al, 2004; Maguire and France, 2014). Furthermore, the
conflicting reports on the antinociceptive effects of Ro 64-6198 in this procedure obscure the
determination of whether a candidate analgesic is a clinically effective analgesic compound (i.e.
a compound sufficiently capable of reducing nociceptive signaling rather than simply producing
a motor-depressant-related reduction in pain responding) or an example of a false-positive (Ko et
al, 2009; Cornelissen et al, 2019).
The second major limitation precluding this procedure from being a strong predictive
translation model is the major discrepancies in dose-requirement for detection of an effect. The
doses typically required to produce an antinociceptive response in assays utilizing endpoints such
as tail-withdrawal tend to be nearly an order of magnitude greater than typically required for
more post-operative cases in humans (Whiteside et al, 2008). For example, the dose of
methadone (3.2 mg/kg) required in these experiments to produce 100%MPE at 54°C also
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produced maximal behavioral suppression in the assay of schedule-controlled responding, and
occasionally required antagonist-reversal. This suggests that the efficacy requirements for
antinociceptive effects are much greater in a preclinical tail withdrawal procedure than those
required for analgesic effects in clinical settings. One negative consequence of these
discrepancies could be that the dose-ratios of opioid combinations chosen for preclinical
experiments (especially if based upon antinociceptive ED50’s) could be massively greater than
those clinically relevant. This could result in determining drug and dose relationships that are
entirely irrelevant for translatability and may be entirely different than the relationships between
those drugs at clinically relevant dose-ratios. Therefore, not only is this procedure capable of
producing false-positives, but potentially also false-negatives.
Finally, this procedure is also severely limited in its ability to produce highly translatable
results due to the challenging nature of chronic dosing in such experiments. Pain remains a
chronic condition in a number of patients requiring novel and improved treatments. Clinically
relevant experimental designs might necessitate more chronic administration to include variables
such as antinociceptive tolerance and metabolic alterations, which are likely to greatly impact the
progression and treatment of pain in humans (Whiteside et al, 2008).

Schedule-Controlled Responding
Schedule-controlled responding provides one complementary dependent measure to
determine behavioral selectivity when using a pain-stimulated behavior such as the warm-water
tail withdrawal procedure to study antinociception. In addition, the schedule-controlled
responding procedure allowed for the calculation of an experimental “therapeutic index” as one
measure of the range of the –fold doses at which a drug can be administered without recruiting a
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specific undesirable effect. For example, aim 1 determined the experimental therapeutic index
for oxycodone to be five, meaning that oxycodone was five times more potent to produce
antiallodynia than sedation. This index does provide some clinical utility and translatability as
one of the major goals for pain management is to adequately mitigate pain symptoms and restore
daily life function and improve quality of life metrics (Wells et al, 2008). Although this measure
is useful to identify selectivity in antinociceptive effects and may have some clinical relevance, it
is maybe potentially more fruitful to employ a multi-modal assessment of a number of
undesirable side effects in future experiments.
Arguably, the most detrimental undesirable MOR agonist effects of greatest concern are
lethality and abuse; these endpoints would be best measured via investigation of respiratory
depression and reinforcing effects. In support of these MOR agonist effects being of the greatest
concern, and therefore the most important to monitor in any potential opioid-combination
experiments, is the Volkow and Collins (2017) report on addressing the opioid crisis which
outlined the need for novel opioid reversal interventions, opioid use disorder treatments, and
non-addictive treatments for pain. In light of this, there may be side effects of greater
significance to investigate in opioid-combination experiments (in an attempt to potentially
mitigate) as compared to sedation. This will be further elaborated upon in the proposed
alternatives section.
Proposed Alternatives
1) Future preclinical pain research should utilize complementary pain-stimulated and
pain-depressed behaviors to assess therapeutic effects of novel analgesics and analgesic adjuncts.
Employing both pain-stimulated and pain-depressed behavioral assays would likely mitigate the
probability of false-positive analgesic compounds. Moreover, the clinical experience of pain
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would be more closely modeled by pain-depressed behaviors, thus would likely serve as a strong
predictor of clinical outcomes.
2) Future preclinical pain research should also utilize complementary behaviors to assess
undesirable effects. For example, two prominent undesirable effects of MOR agonists are
respiratory depression and abuse liability, in addition to behavioral depression/sedation. This is
an imperative measure to employ in future research because of the danger that these effects can
have on both the user and the society, thus it is important to monitor that adjuncts are not
exacerbating the abuse potential or lethality of the opioids they are being combined with.
3) Given the additional ethical considerations involving the use of nonhuman primates in
preclinical pain research, the utility of nonhuman primates as research subjects in future
preclinical pain research will be limited. Thus, future experiments should aim to utilize rodent
models and strive to develop novel paradigms to best improve translatability.
However, if the preclinical approach to opioid combination medication is to continue
being utilized, even in a solely informative capacity, it is imperative for this body of data to
further inform improvements that can be made. Firstly, there needs to be a paradigm shift in the
field moving from the antiquated reliance upon pain-stimulated behaviors to probe
antinociceptive effects to employments of pain-depressed behaviors. These behaviors are much
more similar to the human clinical condition of pain and are hypothesized to have higher
predictive validity of analgesic effectiveness in humans (Negus, 2019). Secondly,
complementary measures of undesirable effects should be more focused on investigating the
clinically concerning MOR side effects such as respiratory depression and abuse liability. Thus,
opioid-combination experiments should be more likely to include these secondary measures
probed with assays such as plethysmography, self-administration, or drug-discrimination to
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determine the potential of candidate receptor systems to mitigate lethality and abuse cause by
MOR agonists. Finally, preclinical experiments should be designed to more closely resemble a
human pain condition in which the patient’s treatment is impacted by factors such as
antinociceptive tolerance and metabolic factors. This would be accomplished with more longterm studies with increased daily dosing frequency to more accurately model the regimen of
patients receiving pain medication. Moreover, a less transient and “escapable” pain stimulus
would more likely reflect the progression of the patient’s state as these factors are very likely to
impact the ability of the analgesic to effectively relieve pain.
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